
DRAFT

**Revised Guidelines for HIV Counseling,
Testing, and Referral**

DRAFT

October 17, 2000

Centers for Disease Control and Prevention

Contents

List of Expert Consultants and Authors and Acknowledgments

Summary

1.0 About the Guidelines

- 1.1 Who Should Read the Guidelines
- 1.2 Obtaining Additional Copies of the Guidelines
- 1.3 Additional Resources

2.0 HIV Counseling, Testing, and Referral Services: An Overview

- 2.1 Evolution of the HIV Counseling, Testing, and Referral Guidelines
- 2.2 Current Status of HIV and HIV Counseling, Testing, and Referral Services
- 2.3 Goals of HIV Counseling, Testing, and Referral Services
- 2.4 Essential Elements of HIV Counseling, Testing, and Referral Services
- 2.5 Routine vs. Targeted HIV Counseling, Testing, and Referral Services
 - 2.5.1 Routinely Recommended Counseling, Testing, and Referral Services
 - 2.5.2 Routinely Recommended Testing and Targeted Counseling, Testing, and Referral Services
 - 2.5.3 Targeted Counseling, Testing, and Referral Services
 - 2.5.4 Recommended Counseling, Testing, and Referral Services for Clients with Prevention Treatment Potential
 - 2.5.5 Determining Whether a Setting Has “High” or “Low” Prevalence and Setting Service Priorities
 - 2.5.6 Determining Individual Client Risk Through Risk Screening

3.0 HIV Counseling

- 3.1 Background
- 3.2 Goals
- 3.3 Information Dissemination
- 3.4 HIV Prevention Counseling
 - 3.4.1 Definition
 - 3.4.2 Who Should Receive Prevention Counseling?
 - 3.4.3 Prevention Counseling Models

- 3.4.4 Elements of HIV Prevention Counseling
- 3.4.5 Who Should Deliver Prevention Counseling?
- 3.4.6 Additional Counseling Considerations in Special Situations
- 3.4.7 Addressing Barriers to HIV Prevention Counseling
- 3.4.8 Ensuring High-Quality HIV Prevention Counseling

4.0 HIV Testing

- 4.1 Background
- 4.2 Goals
- 4.3 Who Should Offer Testing?
- 4.4 Who Should Be Tested?
- 4.5 Addressing Barriers to HIV Testing
- 4.6 Laboratory Characteristics of HIV Test Technologies
- 4.7 Interpreting HIV Test Results
 - 4.7.1 Positive HIV Test Results
 - 4.7.2 Negative HIV Test Results
 - 4.7.3 Indeterminate HIV Test Results
 - 4.7.4 Inconclusive HIV Test Results
- 4.8 Informing Clients of Test Results
 - 4.8.1 Increasing Receipt of HIV Test Results
 - 4.8.2 Current Considerations: Rapid Tests
- 4.9 Subsequent Testing in HIV-Uninfected Clients
 - 4.9.1 Recent Exposure
 - 4.9.2 Single Possible or Known Exposure
 - 4.9.3 Ongoing Exposure
 - 4.9.4 No Identifiable Risk
 - 4.9.5 Special Considerations
- 4.10 Ensuring High-Quality Testing

5.0 HIV Referral

- 5.1 Background
- 5.2 Goals
- 5.3 Definition
- 5.4 Who Should Receive Referrals?
- 5.5 Typical Referral Needs

- 5.6 Implementing and Managing Referral Services
 - 5.6.1 Assessing Client Referral Needs
 - 5.6.2 Planning the Referral
 - 5.6.3 Facilitating Client Access to Services
 - 5.6.4 Documenting Referral and Follow-Up
- 5.7 Ensuring High-Quality Referral Services
 - 5.7.1 Education and Support of Staff
 - 5.7.2 Provider Coordination and Collaboration
 - 5.7.3 Referral Resources

6.0 HIV Counseling, Testing, and Referral in Nontraditional Settings

- 6.1 Background
- 6.2 Ensuring High-Quality Services in Nontraditional Settings

7.0 Quality Assurance and Evaluation of HIV Counseling, Testing, and Referral Services

- 7.1 Quality Assurance
- 7.2 Evaluation
 - 7.2.1 Data
 - 7.2.2 Confidentiality
 - 7.2.3 Ensuring High-Quality Evaluation

Glossary

References

List of Table/Figures/Boxes

Table. Performance Attributes and Potential Applications of FDA-Approved HIV Test Technologies

Figure 1. Counseling, testing, and referral for settings where HIV prevalence is high and the client population is at increased behavioral risk for HIV, regardless of setting prevalence.

Figure 2. Counseling, testing, and referral for settings where HIV prevalence is high.

Figure 3. Counseling, testing, and referral for settings where HIV prevalence is low and the client population is generally not at increased behavioral risk for HIV.

Figure 4. The HIV-1 testing algorithm.

- Box 1. HIV Counseling, Testing, and Referral Settings
- Box 2. Goals of HIV Counseling, Testing, and Referral Services
- Box 3. Examples of Strategies to Elicit Client-Reported HIV Risk
- Box 4. Clients Who Should Receive HIV Counseling, Testing, and Referral
- Box 5. Examples of Directed vs. Open-Ended Questions
- Box 6. Examples of Global vs. Specific Risk-Reduction Steps for HIV Prevention Counseling
- Box 7. Contents of Referral Resource Guide

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.

List of Expert Panelists and Authors

Expert Panelists: Terje Anderson, National Association of People with AIDS; David Atkins, Agency for Health Care Research and Policy; Catherine Baker, California Department of Health; Ronald Bayer, Columbia University; Frank Beadle de Palomo, Academy for Educational Development; Gail Bolan, California Department of Health; Carol Browning, Rhode Island Department of Health; Scott Burris, Temple University School of Law; Amy DeGross, Centers for Disease Control and Prevention (CDC); John Douglas, Colorado Department of Health; Martin Fishbein, The Annenberg School for Communication; Alice Gandelman, California Department of Health; Cynthia Getty, CDC; Lawrence Gostin, Georgetown University; Khurram Hassan, Grady Hospital; Thomas Hearn, CDC; Michael Johnson, Health Resources and Services Administration; William Kassler, New Hampshire Department of Health; Marlene LaLota, Florida Department of Health; Michael Lindsay, Emory University; Michael Merson, Yale University; Steve Morin, University of California San Francisco AIDS Research Institute; James Pearson, Division of Consolidated Lab Services, Virginia; Beny Primm, Addiction Research and Treatment Corporation; Joel Rosenstock, infectious disease specialist, private practice, Atlanta, Georgia; Peter Salovey, Yale University; Charles Schable, CDC; Kathleen Sikkema, Yale University School of Medicine; Edith Springer, Harm Reduction Training Institute; Janis Spurlock-McLendon, State of Connecticut Department of Public Health; Lee Trevithick, Youth Care; and James Welch, Delaware Division of Public Health

Authors: Beatrice Divine, CDC; Stacie Greby, CDC; Ken Hunt, CDC; Mary Kamb, CDC; Liisa Randall, National Alliance of State and Territorial AIDS Directors; Richard Steketee, CDC, and Lee Warner, CDC

Acknowledgments

We thank the many health professionals, both within CDC and outside CDC (at Health Resources and Services Administration, National Alliance of State and Territorial Directors, academic institutions, health departments, health-care organizations, and many other sites throughout the country), who participated in early surveys to assess user need, assisted in formulating key questions, and provided helpful comments on draft versions of these guidelines.

We also thank Jennifer Chapman, Steven Connor, and Parag Sanghvi, graduate students/research assistants working with the Prevention Services Research Branch, National Center for HIV/AIDS,

Sexually Transmitted Diseases, and TB Prevention, CDC, for their assistance.

1 **Summary**

2 These guidelines revise and replace the previous guidelines, *HIV Counseling, Testing, and Referral*
3 *Standards and Guidelines* (CDC, 1994). The guidelines contain recommendations for policy developers
4 and service providers of human immunodeficiency virus (HIV) counseling, testing, and referral services.
5 To develop these guidelines, the Centers for Disease Control and Prevention (CDC) used an evidence-
6 based approach advocated by the U.S. Preventive Services Task Force and public health practice
7 guidelines. The recommendations are based on the combined weight of the evidence from all available
8 scientific sources; where evidence is lacking, expert opinion of “best practices” has been used.

9 Important scientific and programmatic advances in HIV counseling, testing, and referral, as well as
10 advances in prevention and treatment and care of HIV-infected persons, have prompted this revision.
11 With these advances, the need for early detection of HIV infection has become even more compelling, as
12 early detection can benefit infected persons as well as reduce risk of transmission to others. Examples of
13 recent advances include demonstrated efficacy of high-quality HIV prevention counseling models aimed
14 at behavioral risk reduction; effective treatments for HIV infections and opportunistic infections; effective
15 treatment regimens for preventing perinatal transmission; new test technologies; and recognition of the
16 need for systems of referrals to medical, prevention, and psychosocial support services.

17 Although many aspects of the earlier CDC HIV guidelines remain unchanged (e.g., encouragement of
18 confidential and anonymous HIV testing, informed consent, and provision of high-quality HIV prevention
19 counseling that focuses on the clients’ own risks and, whenever possible, is done in association with HIV
20 testing), the current guidelines differ in several respects, including the following:

- 21 • They give guidance to all current and potential providers of voluntary HIV counseling, testing, and
22 referral services, not only to those in the public sector.
- 23 • They acknowledge the need for flexibility in their use, depending on providers’ situations and
24 clients’ needs.
- 25 • They encourage an easier and more streamlined process for both clients and providers.
- 26 • They underscore the importance of making counseling, testing, and referral services more
27 accessible and available.
- 28 • They underscore the need to increase the numbers of infected persons who know their HIV
29 status.
- 30 • They encourage anonymous testing to be available nationwide.
- 31 • They review newly available HIV testing methods and appropriate uses and settings.
- 32 • They address ways to improve the quality and provision of HIV prevention counseling.

- 33 • They differentiate between “information dissemination” and “prevention counseling” in the
- 34 context of the counseling session.
- 35 • They strengthen the recommendation to identify and meet referral needs.

36

1.0 About the Guidelines

37

1.1 Who Should Read the Guidelines

38

These guidelines have been developed for providers in the many settings that offer voluntary human immunodeficiency virus (HIV) counseling, testing, and referral services—in the public and private sectors, urban and rural areas, and settings with high or low HIV prevalence (Box 1). The guidelines may also be useful for counseling, testing, and referral services in other settings (e.g., insurance, military, blood donation). The U.S. Public Health Service has specific responsibilities for ensuring the quality of services in publicly funded programs, and some aspects of the guidelines focus on these programs.

44

The guidelines are intended to be used in developing counseling, testing, and referral services and policies. The recommendations should be tailored to fit the needs of clients, communities, and programs within local, state, and federal rules and regulations.

47

Box 1. HIV Counseling, Testing, and Referral Settings.

48

Settings that provide HIV counseling, testing, and referral services include but are not limited to the following:

49

50

Adolescent health clinics

Drug or alcohol prevention and treatment programs

Men's health clinics

Migrant health centers

Outreach programs (e.g., syringe exchange programs)

51

AIDS services organizations

Family planning clinics

Prenatal clinics

52

Clinics serving men who have sex with men

Freestanding HIV test sites

Publicly funded counseling and testing sites

54

Community-based organizations

Hospital emergency rooms

STD clinics

55

Community health centers

Hospitals/other urgent care centers

TB clinics

56

Correctional facilities

Managed care organizations/other private service providers

Women's health clinics

57 **1.2 Obtaining Additional Copies of the Guidelines**

58 Single copies of this report can be obtained from (*information to be supplied later*). The guidelines will
59 be updated periodically and posted electronically. Information can be obtained from

- 60 • Centers for Disease Control and Prevention (CDC) at www.cdc.gov and 1-800-xxx-xxxx
- 61 • HIV/AIDS Treatment Information Service at www.hivatis.org and 1-800-448-0440
- 62 • CDC's National Prevention Information Network at www.cdcnpin.org and 1-800-458-5231

63 **1.3 Additional Resources**

64 Additional information on HIV counseling, testing, and referral services can be obtained from

- 65 • CDC's National Center for HIV, STD, and TB Prevention at www.cdc.gov/nchstp/od and 1-
66 800-458-5231
- 67 • CDC's National Prevention Information Network at www.cdcnpin.org and 1-800-458-5231
- 68 • HIV/AIDS Treatment Information Service at www.hivatis.org and 1-800-448-0440
- 69 • AIDS Clinical Trials Information Service at www.actis.org and 1-800-874-2572

70 **2.0 HIV Counseling, Testing, and Referral Services: An Overview**

71 **2.1 Evolution of the HIV Counseling, Testing, and Referral Guidelines**

72 These guidelines revise and update several sets of CDC guidelines for HIV counseling, testing, and
73 referral. The first CDC guidelines, published in 1986, highlighted the importance of offering voluntary
74 testing and counseling services and maintaining confidential records (1). One year later, 1987 guidelines
75 emphasized the need to decrease any barriers to counseling and testing, especially disclosure of personal
76 information (2). In 1993, an additional report (3) was published to supplement and update the 1987
77 guidelines; it described the model of HIV prevention counseling currently recommended—an interactive
78 rather than didactic model that focuses on an individualized HIV risk-reduction plan. The 1994 report,
79 *HIV Counseling, Testing and Referral Standards and Guidelines*, focused on standard testing
80 procedures and reiterated the importance of the HIV prevention counseling model and the need for
81 confidentiality of counseling services (4).

82 During the last 6 years, several important advances have occurred in the areas of HIV counseling, testing,
83 and referral. The recommendations in this document reflect this new knowledge.

- 84 • Controlled trials showed that the high-quality HIV prevention counseling model encouraged by
85 CDC in the 1993 and 1994 guidelines (3,4) is efficacious for changing behavior and reducing the
86 incidence of sexually transmitted diseases (STDs) in HIV-uninfected persons at increased risk
87 (5). Furthermore, mounting evidence supports the efficacy of other counseling models aimed at
88 HIV prevention (5-26).
- 89 • Treatment for HIV with antiretroviral therapy (27) and for opportunistic infections (28) has
90 been found to be effective, improving quality and duration of life.
- 91 • Medical therapy to dramatically reduce the risk of perinatal HIV transmission has been
92 identified and become available (29,30).
- 93 • New testing technologies (e.g., oral fluid, urine, and rapid tests) are increasingly available (31).
94 The flexibility that these tests provide may help increase acceptance of testing and receipt of
95 test results and identify infection earlier (32).
- 96 • Guidance on partner counseling and referral services, prevention case management, prevention
97 and control of STDs, and prevention of opportunistic infections (33-36) has been published or
98 updated by CDC.

99 Because of these advances, CDC, in consultation with multiple partners, revised the 1994 guidelines using
100 an evidence-based approach (37,38) and expanded the target audience to all providers of HIV counseling

101 and testing services in the United States (37). Where scientific findings were lacking, recommendations
102 were guided by “best practices” from expert opinion. The authors of these guidelines employed a five-
103 step approach to the revision process:

- 104 • **Address user needs.** The authors conducted a survey of publicly funded sites to assess user
105 satisfaction with previous (1994) CDC guidelines for HIV counseling, testing and referral. They
106 also consulted with both internal and external content experts on key areas to address in the
107 revised guidance.
- 108 • **Review literature.** They screened more than 5,000 abstracts and reviewed and synthesized
109 into Tables of Evidence more than 600 relevant publications (*citations to be posted on the*
110 *Web site*). In addition, 22 previously published CDC guidelines related to HIV counseling,
111 testing, and referral were summarized.
- 112 • **Obtain technical expert opinion.** The authors convened a panel of technical experts from
113 public and private sectors; governmental and nongovernmental agencies; and legal, ethical, and
114 policy fields. This panel reviewed summary recommendations.
- 115 • **Obtain user input.** Internal CDC comment, public and private provider assessment, key
116 consultant interviews, broad external review, and public comment through the Federal Register
117 were obtained.
- 118 • **Publish electronically and in hard copy.**

119 The revised guidelines continue to support offering voluntary HIV testing in both confidential and
120 anonymous formats, obtaining informed consent, and providing HIV prevention counseling that is focused
121 on the clients’ own risks and, whenever possible, is done in association with HIV testing. These new
122 guidelines expand on or differ from previous guidelines in the following respects:

- 123 • Provide guidance for both private and public providers of HIV counseling, testing, and referral
124 services.
- 125 • Acknowledge the need for flexibility in implementing the guidelines so that providers can apply
126 them as appropriate for their own circumstances (given their particular client base, prevalence
127 level, and resources) to best meet client needs.
- 128 • Provide additional guidance to improve the quality and provision of HIV prevention counseling
129 and describe new information on its proven efficacy in reducing high-risk behaviors and new
130 STDs.
- 131 • Strengthen CDC’s existing recommendation that anonymous testing be broadly available.
- 132 • Revise goals for HIV counseling, testing, and referral to emphasize increasing the numbers of
133 HIV-infected persons who know their HIV infection status and know it early in the course of
134 their infection.

- 135 • Provide current information on newly available HIV testing methods and appropriate uses and
136 settings for these new tests.
- 137 • Emphasize the importance of ensuring that providers assist clients in accessing needed medical
138 and other support services.
- 139 • Describe in greater detail assessment and management of referrals.
- 140 • Encourage offering high-quality services in nontraditional settings to facilitate access for those
141 at increased risk for HIV who are not being reached by existing services.
- 142 • Strengthen endorsement of the role of quality assurance and evaluation in counseling, testing,
143 and referral services.

144 **2.2 Current Status of HIV and HIV Counseling, Testing, and Referral Services**

145 HIV infection and HIV-related diseases have become a leading cause of illness and death in the United
146 States in the last two decades. As of the end of 1999, it is estimated that more than 430,000 persons have
147 died from HIV/AIDS, and nearly 290,000 persons are living with AIDS (39). Approximately 800,000 to
148 900,000 persons in the United States are infected with HIV(40); it is estimated that as many as 275,000 of
149 these persons may not know that they are infected (41).

150 Many types of settings in the United States offer HIV counseling, testing, and referral services. Voluntary
151 testing can be obtained in both public and private medical care settings, such as physicians' offices,
152 hospitals, managed care organizations, and publicly funded clinics (42). Testing is also provided in
153 nontraditional settings (community-based and outreach settings), in which persons at increased risk for
154 HIV are targeted. Sample collection can even be done outside a medical or field facility—through home
155 collection kits (43). Most HIV tests, however, are conducted in the private sector (42).

156 A substantial number of opportunities for HIV prevention are being missed. In publicly funded sites, at
157 least 70% of persons tested have received their test results and some counseling, but the numbers of
158 persons receiving HIV prevention counseling and receiving referrals are likely much lower. In many
159 potential testing settings (e.g., emergency rooms), HIV prevention counseling and HIV testing are not
160 uniformly offered. Data regarding types and completion of referral are not routinely collected in many
161 settings.

162 **2.3 Goals of HIV Counseling, Testing, and Referral Services**

163 To achieve optimal health for the individual and the public, high-quality HIV counseling, testing, and
164 referral services have the following goals (Box 2). It is essential that these services be easily accessible
165 and available and that the process be easy and streamlined for both clients and providers.

166 **Box 2. Goals of HIV Counseling, Testing, and Referral Services**

- 167 • Ensure that HIV-infected persons receive high-quality HIV prevention counseling to reduce
168 their risk of transmitting HIV to others; have early knowledge of their HIV status; and have
169 access to appropriate medical, prevention, and psychosocial services.
- 170 • Ensure that persons at increased risk for HIV receive high-quality HIV prevention counseling
171 to reduce their risk of acquiring HIV infection; know their HIV status; and have access to
172 appropriate medical, prevention, and psychosocial support services.
- 173 • Ensure that persons who are offered or receive HIV testing are provided information about the
174 ways in which HIV is transmitted and can be prevented and about the meaning of the HIV test
175 results.

176 **2.4 Essential Elements of HIV Counseling, Testing, and Referral Services**

177
178 The following elements are critical in offering high-quality HIV counseling, testing, and referral services:

- 179 • **Strictly protect confidentiality for clients who are offered or request and/or who receive**
180 **HIV services.** Information about a client's use of HIV services should remain private
181 (confidential). Personal information is not to be divulged to others in ways that are inconsistent
182 with the client's original consent.
- 183 • **Obtain informed consent before HIV testing.** The provider must obtain informed consent
184 before the HIV test is conducted. Accepting or refusing testing must not have detrimental
185 consequences to the quality of care offered. Documentation of informed consent should be in
186 writing, preferably with the client's signature. In situations where written consent cannot be
187 obtained, documentation of verbal consent or refusal in the client's record may be sufficient.
- 188 • **Provide clients the option of anonymous HIV testing.** Anonymous testing (testing
189 information not documented in client's record) has been used widely and effectively and may
190 offer important benefits for the health of individuals and the public, such as earlier entry into

- 191 medical care (44). Some persons who would otherwise not have been tested may seek
192 anonymous HIV testing and learn their HIV status. Consistent with current public health best
193 practice, states in which anonymous testing is not available should reconsider their policy.
194 Confidential testing (testing information documented in client's record) is preferred when the
195 client has no clear preference regarding testing format. Confidential testing may facilitate linkage
196 to follow-up counseling and referral for needed services after test results are received.
- 197 • **Adhere to local, state, and federal regulations and policies that govern provision of HIV**
198 **services.** Laws at the local, state, and federal levels may address many aspects of HIV
199 services. Laws may also regulate how services can be provided to particular persons, e.g.,
200 minors. In addition, policy, local ordinances, funding source requirements, and planning processes
201 will also affect a provider's decisions about which services to provide and how to provide them.
 - 202 • **Provide services responsive to client and community needs and priorities.** Providers
203 should work to remove barriers and tailor services to individual and community needs. To help
204 ensure that clients find services accessible, services can be offered in nontraditional settings (e.g.,
205 outreach settings); clinic/office hours can be expanded or altered; unnecessary delays can be
206 eliminated through more efficient organization of operations (e.g., integrating counseling and
207 testing for STDs/HIV with counseling and testing for hepatitis); test results can be obtained more
208 -easily (e.g., provided at the time of testing with rapid testing or, in certain situations, by
209 telephone); and less-invasive specimen collection can be used (e.g., oral fluid, urine, finger-stick
210 blood).
 - 211 • **Provide services that are culturally, linguistically, gender-, and age-appropriate.** The
212 client's culture, language, literacy level, gender, and age may affect how the client seeks, accepts,
213 and understands HIV services. Providers should take these factors into consideration when
214 designing and providing HIV services.
 - 215 • **Ensure high-quality services.** To ensure that clients receive services of high quality, providers
216 should develop and implement written quality assurance and program evaluation procedures to
217 ensure ongoing effective services that serve client and community needs.

218 **2.5 Routine vs. Targeted HIV Counseling, Testing, and Referral Services**

219 Numerous studies have shown that both in higher-prevalence settings and settings serving clients at
220 increased behavioral risk for HIV infection, targeting clients for HIV testing on the basis of reported risk

221 factors will not necessarily identify and might not offer services to many HIV-infected clients (45-53).¹
222 However, in low-prevalence populations, where most clients have minimal risk, targeting clients for HIV
223 testing on the basis of risk screening may be more feasible and cost-effective for identifying small
224 numbers of HIV-infected persons (54).

225 For these reasons, health-care providers should consider both setting HIV prevalence and behavioral HIV
226 risk of the client population when determining whether to recommend HIV prevention counseling, testing,
227 and referral to all clients or to recommend these services to selected clients. A third factor may also
228 influence this decision: the availability of potentially beneficial treatment for HIV prevention may support
229 routine recommendations for testing, even in low-prevalence or low-risk settings, for example, in HIV-
230 infected pregnant women for prevention of perinatal transmission (see simultaneously published guidelines
231 on preventing perinatal HIV transmission) (30) or persons who have been occupationally exposed to HIV.

232 Although HIV counseling, testing, and referral are naturally linked services, these guidelines acknowledge
233 public and private providers' needs for flexibility. Therefore, the guidelines recognize, for example, that a
234 provider may offer prevention counseling services without being able to offer an HIV test or a provider
235 may be able to offer the test without being able to offer prevention counseling services. In either case,
236 providers should always give referrals to accompany counseling or testing.

237 **2.5.1 Routinely Recommended Counseling, Testing, and Referral Services**

238 **HIV prevention counseling, testing, and referral are routinely recommended for all clients in**
239 **settings where the client population is generally at increased behavioral risk of acquiring or**
240 **transmitting HIV infection (see below), regardless of setting prevalence.**


241
242 In the settings described above, providers should recommend HIV prevention counseling, testing, and
243 referral for all clients (Figure 1) and provide these services on site.

244 Examples of settings that may serve client populations at generally increased behavioral risk for HIV are
245 STD clinics, adolescent health clinics with high STD rates, clinics serving men who have sex with men,
246 drug or alcohol prevention and treatment programs, freestanding HIV test sites, homeless shelters,
247 correctional facilities, juvenile detention centers, outreach programs (e.g., syringe exchange programs),

¹Even in high prevalence settings, HIV testing need not be routinely recommended to clients at minimal risk (e.g., persons not sexually active). In addition to age and behavioral parameters, other local factors could be considered. Providers could consult local health departments.

248 prisons, and tuberculosis (TB) clinics.

Figure 1. Counseling, testing, and referral for settings where the entire client population is at increased behavioral risk for HIV*, regardless of setting prevalence.



* Such settings might include sexually transmitted disease clinics, drug treatment centers, and needle exchange programs.

269 **2.5.2 Routinely Recommended Voluntary Testing and Targeted Counseling, Testing, and**
270 **Referral Services**


271 **In settings where HIV prevalence is high (e.g., $\geq 1\%$, see 2.5.5), voluntary HIV testing is**
272 **routinely recommended for most persons. For persons not likely to be at increased risk (e.g.,**
273 **persons not sexually active and who do not inject drugs), risk screening should be conducted,**
274 **and clients found to be at increased risk should be tested and receive prevention counseling, as**
275 **well as referral to any needed services.**

276 In high prevalence settings (e.g., $\geq 1\%$, see 2.5.5), it is desirable that most clients be recommended HIV
277 testing. However, in these settings, some clients are only at minimal risk (e.g., because of lack of sexual
278 activity).² Services should be routinely offered to most clients (see Figure 2), but for those outside
279 specific behavioral or age parameters, services could be targeted based on risk screening. Methods of
280 determining who should not be screened are limited. Evidence suggests that locally applicable factors may
281 be important to consider. Providers may benefit from consulting their local health departments or, through
282 local health departments, local HIV community planning groups to determine if other factors should be
283 considered. Counseling and referral are recommended even if HIV testing is declined.

284

²In many settings, persons older than 54 years of age may also be considered not likely to be at increased risk for HIV.

Figure 2. Counseling, testing, and referral for settings where HIV prevalence is high*.



* $\geq 1\%$ prevalence in the setting or higher prevalence than other settings in the community (see 2.5.5).


**A client who requests a test or has clinical symptoms suggestive of HIV should be given an HIV

317 **2.5.3 Targeted Counseling, Testing, and Referral Services**

318 **In settings where both HIV prevalence is low (e.g., <1%, see 2.5.5) and the client population is**
319 **generally not at increased behavioral risk of acquiring or transmitting HIV infection, HIV**
320 **prevention counseling, testing, and referral services should be targeted on the basis of risk**
321 **screening (see 2.5.6)**

322 Low-prevalence settings where the client population is not at increased risk likely represent the majority
323 of health-care settings. In these settings, if risk screening (see 2.5.6), which assesses an individual client's
324 behavioral and clinical risks for HIV, indicates that a client is at increased risk for HIV, prevention
325 counseling, testing, and referral are recommended (Figure 3). Prevention counseling and referral are
326 recommended even if HIV testing is declined.

Figure 3. Counseling, testing, and referral for settings where HIV prevalence is low* and the client population is generally not at increased behavioral risk for HIV.



* <1% prevalence or lower than other settings in the community (see 2.5.5).

**A client who requests a test should be given an HIV test, information, and HIV prevention counseling.

356 **2.5.4 Recommended Counseling, Testing, and Referral Services for Clients with Prevention**
357 **Treatment Potential**

358 Effective treatment that may reduce the risk for HIV transmission and acquisition exists in a limited
359 number of situations: perinatal transmission, acute occupational exposure, and possibly acute
360 nonoccupational (high-risk sexual or needle-sharing) exposure.

361 Given the availability of such treatment, voluntary HIV testing should be

- 362 • routinely recommended for all pregnant women (30)
- 363 • routinely recommended for clients with acute occupational exposure (55)
- 364 • routinely recommended for clients with acute nonoccupational exposure (e.g., high-risk sexual or
365 needle-sharing)(56)

366 HIV prevention counseling and referral should be

- 367 • targeted to pregnant women on the basis of risk screening (30)
- 368 • routinely recommended to clients with acute occupational exposure (55)
- 369 • routinely recommended to clients with acute nonoccupational exposure (56)

370 For further information, consult the respective guidelines (30,55,56).

371 **2.5.5 Determining Whether a Setting Has “High” or “Low” Prevalence and Setting Service**
372 **Priorities**

373 Limited data exist with which to formulate a general definition for “high” and “low” HIV prevalence and
374 describe how such a definition could assist in developing and prioritizing HIV counseling, testing, and
375 referral services. However, research from the early 1990s for acute care hospitals with $\geq 1\%$ HIV
376 prevalence suggests that routine HIV testing of all patients ages 15-54 years identifies a large proportion
377 of HIV-infected patients in a cost-effective manner (57). This 1% prevalence figure and age range may
378 be used as *very general guidance* for whether or not to routinely recommend HIV counseling and
379 testing.

380
381 The threshold of HIV prevalence that should lead to routine recommendations for HIV testing of all
382 clients within a setting may vary markedly within and across settings and should be made in consideration
383 of available resources. If need be, services could target settings with HIV prevalence rates $<1\%$ but
384 higher than other settings in the community, according to U.S. prevalence data (42,54). If HIV prevalence
385 data are outdated or unknown, providers should consult their local or state health department for
386 assistance in determining appropriate HIV testing, counseling, and referral strategies. In situations where

387 prevalence data are known, providers may also base decisions in part on the behavioral HIV risk of the
388 client population.

389 **2.5.6 Determining Individual Client Risk Through Risk Screening³**

390 Determination of a client's HIV risk through risk screening for the purpose of targeting counseling,
391 testing, and referral services is based on both the client's self-reported behavioral risk and clinical signs or
392 symptoms (e.g., STDs) suggesting increased risk for HIV infection or other signs or symptoms (e.g.,
393 opportunistic infections) suggesting the presence of HIV infection (Box 4). Behavioral risks include, for
394 example, injection drug use or unprotected intercourse with someone at increased risk for HIV.

395 Most primary health-care providers do not ask clients about HIV or other STD risks (58-61), assuming
396 that their clients have less HIV and STD risk than they actually do (62) and thus missing opportunities for
397 HIV counseling and testing or referral for those services. Although risk screening will not identify all
398 HIV-infected persons or persons at increased risk for infection, the use of strategies to identify clients at
399 increased risk (Box 3) could identify many who might otherwise have been missed in low-prevalence
400 settings. Available data do not support the efficacy of any one behavioral risk screening strategy over
401 others (e.g., face-to-face discussion or interviews, self-administered questionnaires, computer-assisted
402 interviews, provider use of simple open-ended questions) (45,54). Because client HIV risk may not
403 always be identified by provider or client, any client who requests a test should be offered one.

³ "Risk screening" differs from "risk assessment," which is a part of HIV prevention counseling (see 3.4.3 and 3.4.4).

404

Box 3. Examples of Strategies to Elicit Client-Reported HIV Risk

405

- Open-ended question by provider:

406

“What are you doing now or what have you done in the past that you think may put you at risk for HIV infection?”

407

408

- Screening questions (checklist) for use with a self-administered questionnaire, face-to-face or computer-assisted interview, or other instrument:

409

“Since your last HIV test (if ever), have you

410

411

- injected drugs and shared equipment (needles, syringes, cotton, water) with others?

412

413

- had unprotected intercourse with someone that you think might be infected (e.g., a partner who injected drugs, has been diagnosed or treated for an STD or hepatitis, or has had multiple sex partners)?

414

415

416

- had unprotected vaginal or anal intercourse with more than one sex partner?

417

- been diagnosed or treated for an STD or hepatitis?

418

- had a positive TB skin test?

419

- had a fever or illness of unknown cause?

420

- been told you have an infection related to a weak immune system?”

Box 4. Clients Who Should Receive HIV Prevention Counseling, Testing, and Referral

- All clients with acute occupational or known sexual or needle-sharing exposure to an HIV-infected person. See guidelines (55,56).
- All clients seeking services in settings with a client population having $\geq 1\%$ * HIV prevalence See 2.5.2.
- All clients seeking services in settings serving client populations at increased behavioral HIV risk (regardless of setting HIV prevalence).
- Individual clients seeking services in settings with $< 1\%$ ** HIV prevalence (see 2.5.3) who
 - specifically request an HIV test;
 - have clinical symptoms suggesting HIV (e.g., fever or illness of unknown origin, positive Mantoux [TB skin] test, opportunistic infection [including TB] without known reason for immune suppression) or suggesting increased risk for HIV (e.g., another STD or bloodborne infection); or
 - self-report HIV risks (Box 3)
- All pregnant women should be tested for HIV regardless of setting prevalence or behavioral risk and should receive HIV prevention counseling and referral on the basis of risk screening (see 2.5.6). See guidelines (30).

* Or higher than other settings in the community.

**Or lower than other settings in the community.

441

3.0 HIV Counseling

442

3.1 Background

443

Since 1985, the recommended HIV counseling model used in the context of HIV testing has evolved from a technical discussion about the HIV test to an interactive counseling approach aimed at reducing clients' personal risk for acquiring or transmitting HIV. The current guidelines continue to recommend providing up-to-date information about HIV prevention and the test whenever HIV testing is done but focus on interactive HIV prevention counseling approaches aimed at personal risk reduction for HIV-infected persons and for uninfected persons at increased HIV risk.

444

445

446

447

448

449

The body of scientific evidence provides convincing support that personalized HIV prevention counseling (i.e., counseling aimed at ways a specific client can reduce his or her own risks) can reduce HIV acquisition among high-risk persons with negative or unknown HIV status (5-26) and transmission from HIV-infected persons (24-26,63-67). In addition, several large trials have found interactive counseling approaches that fully engage the client in the sessions are more effective than purely informational approaches (5,9,18,19). Effective counseling approaches also tend to be directed at clients' personal risks and situations in which those risks occur and at helping clients commit to realistic, concrete steps to reduce those risks (5,7,20). Given limited provider time, a practical question is whether such counseling approaches aimed at personal risk reduction are needed whenever HIV testing is done. Although the body of research strongly supports that HIV prevention counseling can lead to risk reduction among HIV-infected persons (63-67) and uninfected persons with increased HIV risk (5-26), little evidence supports the utility or cost-effectiveness of this type of counseling in uninfected persons with low or no HIV risk.

450

451

452

453

454

455

456

457

458

459

460

461

3.2 Goals

462

HIV counseling seeks to reduce HIV acquisition and transmission through

463

- *Information dissemination*: Providing information about HIV transmission and prevention and the meaning of HIV test results (see 3.3)

464

465

- *HIV prevention counseling*: Helping clients identify the specific behaviors putting them at risk for acquiring or transmitting HIV and commit to steps to reduce their HIV risks (see 3.4).

466

467

3.3 Information Dissemination

468 **All clients who are offered or receive HIV testing should be given information about ways in**
469 **which HIV is transmitted, the importance of obtaining test results, and the meaning of HIV test**
470 **results, even if the test is declined.**

471 Whenever an HIV test is offered, the following information could be provided in a culturally, linguistically,
472 gender-, and age-appropriate manner by means of pamphlets, brochures and/or videos, rather than face-
473 to-face.

- 474 • Information and benefits about the HIV test
 - 475 • Risks for HIV transmission and means by which HIV can be prevented
 - 476 • The importance of obtaining the test results and clear procedures for doing this
 - 477 • The meaning of the test results in clear understandable language*
 - 478 • Where to obtain further information or, if applicable, HIV prevention counseling services
- 479 *An example of such language would be “A negative test means no HIV was found. But if you
480 were exposed to HIV recently—in the last 1-2 months—this test was not able to pick that up.”
481 (See 4.7.2)

482 In addition, in many settings where HIV testing is offered, the following information is useful:

- 483 • Descriptions or demonstrations of how to use condoms correctly
- 484 • Information about risk-free and “safer” sex options (68)
- 485 • Information about other sexually transmitted and bloodborne diseases
- 486 • Descriptions about the effectiveness of using clean needles, syringes, cotton, water, and other
487 drug paraphernalia
- 488 • Information about drug treatment

489 For efficiency, this information could be provided in a pamphlet, brochure, and/or video rather than in a
490 face-to-face encounter with a counselor. This allows face-to-face provider-client interactions to focus on
491 proven-effective prevention counseling approaches (see 3.4). Information should be provided in a manner
492 appropriate for the client’s culture, language, gender, and age (see 2.4), and technical discussions (e.g.,
493 about antibodies or the window period) should be avoided. Certain informational videos and large-group
494 presentations providing explicit information about how to use condoms correctly have been found
495 effective in reducing new STDs (21-23,69). For additional information, contact CDC’s National
496 Prevention Information Network (NPIN) at 1-800-458-5231 or www.cdcnpin.org.

497 **3.4 HIV Prevention Counseling**

498 **HIV prevention counseling should focus on the client’s own unique circumstances and risk and**
499 **should help the client set and reach an explicit behavior change goal that would reduce his or**
500 **her chance of acquiring or transmitting HIV.**

501 **3.4.1 Definition**

502 “HIV prevention counseling” is a process that is aimed at personal HIV risk reduction—that is, a type of
503 counseling with the explicit goal of helping the client identify and commit to a specific behavior change
504 step that will help prevent acquisition or transmission of HIV. HIV prevention counseling engages the
505 client in the session. It is usually, but not always, done in the context of HIV testing.

506 In “client-centered⁴ HIV prevention counseling” (see 3.4.3), sessions are fairly brief (4,5,70); other
507 counseling models are longer or have more sessions (5-12,14-20,71). Regardless of the model used,
508 inherent in HIV prevention counseling is its focus on the client’s personal risks or circumstances and on
509 helping the client set and reach a specific, realistic, risk-reduction goal.

510 **3.4.2 Who Should Receive Prevention Counseling?**

511 **Routine HIV prevention counseling is recommended for all clients in settings where the client**
512 **population is generally at increased behavioral risk for HIV infection, regardless of HIV**
513 **prevalence in the setting. Counseling should be provided on site.**

514 In these settings, clients with ongoing risk behaviors should be linked to additional HIV prevention
515 services, as appropriate. HIV-infected clients should receive ongoing HIV prevention counseling that is
516 applicable to their personal situation.

517 **Targeted HIV prevention counseling is recommended in settings where HIV prevalence is**
518 **high (see 2.5.5) and thus most clients are routinely recommended HIV testing. Results of risk**
519 **screening (see 2.5.6) can be used to determine which clients should be recommended HIV**
520 **prevention counseling.**

⁴The term “client-centered” is used here to mean that the counseling sessions are focused on the client’s own unique risk circumstances, risk behaviors, and prevention needs. It should not be confused with the more intensive client-centered approach advocated by psychologist Carl Rogers, although some skills and strategies that involve the client in the prevention counseling process may be similar.

521
522 In these settings, clients with ongoing risk behaviors identified on risk screening should be linked to
523 additional HIV prevention services, as appropriate. Counseling should be provided on site whenever
524 possible. If counseling cannot be provided on site, clients should be referred to facilities that can provide
525 HIV prevention counseling.

526 **Targeted HIV prevention counseling is recommended for clients in settings where HIV**
527 **prevalence is low (see 2.5.5) and for clients in settings where the client population is not at**
528 **increased behavioral risk for HIV infection. Results of risk screening (see 2.5.6) can be used to**
529 **determine which clients should be recommended HIV prevention counseling.**

530
531 In low-prevalence settings where the client population is not at increased HIV risk, if HIV prevention
532 counseling and/or testing does not occur on site, a clear referral system should be established and
533 maintained for clients at increased risk.

534 In addition to HIV testing, risk screening (see 2.5.6) is recommended for all pregnant women. For
535 women identified as having increased HIV risk, HIV prevention counseling is recommended and ideally
536 should be done at the testing site. However, in settings where such counseling is not available, referral
537 should be offered.

538 **Counseling should not be a barrier to HIV testing. Similarly, a focus on increased HIV testing**
539 **should not be a barrier to providing effective HIV counseling services for clients determined to**
540 **be at increased risk for acquiring or transmitting HIV.**

541 Knowledge of HIV status is a critical HIV prevention strategy. Lengthy counseling sessions should not
542 impede a client's decision to have an HIV test. However, because evidence is strong that effective
543 counseling can reduce high-risk behaviors leading to HIV acquisition (5-26), the opportunity to apply high-
544 quality HIV prevention counseling when HIV testing is offered to persons at increased risk for HIV
545 should not be missed.

546 **3.4.3 Prevention Counseling Models**

547 Several models for HIV prevention counseling done with testing have been developed, evaluated in
548 controlled studies, and found efficacious in changing behavior or reducing sexually transmitted infections.
549 These have included individual face-to-face counseling (5,13), large- and small-group counseling with a
550 facilitator (7,18,20,71), and video-based counseling (21). Many of the counseling protocols are available

551 for use by counselors. (For additional information about interventions, see The Compendium of HIV
552 Prevention Interventions with Evidence of Effectiveness,
553 http://www.cdc.gov/nchstp/hiv_aids/pubs/hivcompendium.pdf).

554 **Client-centered HIV prevention counseling.** Since 1993, CDC has recommended one interactive
555 counseling approach, client-centered HIV prevention counseling (3,4). Client-centered HIV prevention
556 counseling involves two face-to-face sessions with a provider or counselor (3-5,70,72,73). First
557 recommended for use in publicly funded HIV clinics in 1993, this model takes advantage of a two-step
558 HIV testing approach in which clients are physically present at a setting for the HIV test (pretest
559 counseling) and then return for HIV test results (posttest counseling). Sessions may require 15 to 20
560 minutes (including testing and referral) for clients at increased risk for HIV, but could take only a few
561 minutes for clients at lower risk. In the first session, a personalized risk assessment⁵ encourages clients to
562 identify, understand, and acknowledge their own behaviors and circumstances that put them at increased
563 risk for acquiring HIV. The session includes an exploration of previous attempts to reduce risk and
564 identification of successes and challenges in previous risk reduction. This in-depth exploration of risk
565 behaviors (risk assessment) allows the counselor to help clients consider ways to reduce their personal
566 risk and commit to a single, explicit step to reduce risk. In the second session, which occurs when HIV
567 test results are provided, the counselor discusses the test results, asks the client to describe the risk-
568 reduction step attempted (acknowledging positive steps made), helps the client identify and commit to
569 additional behavioral steps, and provides appropriate referrals.

570 Client-centered HIV prevention counseling has been shown to be effective at reducing high-risk sex
571 behaviors and new STDs in a large randomized trial evaluating HIV counseling (5). The model has been
572 found to be feasible to use even in busy publicly funded clinics; acceptable to clients, counselors, and
573 health-care providers (72); and cost-effective at preventing STDs in persons with sexual risk behaviors
574 (74-76). The approach appears to be especially effective among adolescents and persons with ongoing
575 sexual risk behaviors (e.g., newly diagnosed STDs) (5). Although the benefits of this model in reducing
576 high-risk drug behaviors are as yet unknown, similar counseling approaches engaging clients in personal
577 exploration of risks and setting concrete risk-reduction goals appear to be effective in reducing risky drug
578 use behaviors (24-26,77).

⁵Risk assessment is an essential element of HIV prevention counseling in which the client and counselor work to understand and acknowledge the client's personal risk(s) for HIV. Risk assessment is not synonymous with risk screening, which helps determine which individual clients in a population require HIV prevention services.

579 Observational studies and reviews of programs suggest that many counselors are still unfamiliar with the
580 specific goals of the client-centered HIV prevention counseling model (70,73,78). The term “client-
581 centered” is sometimes misinterpreted to mean “face-to-face,” and thus in many HIV test sites, the
582 provider delivers a face-to-face informational message in response to a check-list risk assessment. In this
583 document, this type of “counseling” is considered to be “information dissemination” and “data collection.”
584 It tends not to encourage client participation or discussion of personal risk and seldom focuses on personal
585 goal setting. The term “client-centered” is also sometimes misinterpreted to mean the counselor should
586 avoid directing the session. Although attentive listening and respect for clients’ concerns are important
587 elements of good counseling, the primary goal of client-centered HIV prevention counseling is risk
588 reduction. In client-centered counseling, risk reduction is brought about through an in-depth, personalized
589 risk assessment and negotiation of a risk-reduction step that is concrete, acceptable, and achievable. HIV
590 prevention counseling will usually require provider training and support and ongoing quality assurance to
591 achieve optimal benefit (see 3.4.8). Providers can contact their state health department HIV/AIDS
592 program office for information on local training opportunities or NPIN (www.cdcnpin.org; 1-800-458-
593 5231) for training materials.

594 **3.4.4 Elements of HIV Prevention Counseling**

595 Regardless of the specific HIV prevention counseling model used, some counseling components have
596 been repeatedly used in effective interventions and are recognized by many experts as critical in
597 counseling success (Expert Panel Meeting, Atlanta, Georgia, February 1999).

598 **The following elements should be part of all HIV prevention counseling sessions:**

599 **Keep the session focused on HIV risk reduction.** Each counseling session should be tailored to
600 address the personal HIV risk of the client rather than providing a predetermined set of information
601 unrelated to the client’s situation or allowing the session to be distracted by the client’s additional problems
602 unrelated to HIV. Counseling techniques such as use of open-ended questions (Box 5) and role-play
603 scenarios, attentive listening, and maintaining a nonjudgmental and supportive approach can encourage the
604 client to remain focused on personal HIV risk reduction.

605 **Include an in-depth, personalized risk assessment.** This risk assessment allows the counselor and
606 client to identify, acknowledge, and understand the specific details of the client’s own HIV risks and the
607 context in which risks occur (19,79,80). Keeping the risk assessment personal, as opposed to global, will
608 help the client identify concrete and acceptable protective measures to reduce personal HIV risk (Box 6).
609 The risk assessment should explore previous risk-reduction efforts and identify successes and challenges
610 in those efforts. Factors associated with continued risk behavior that may be important to explore include

611 intoxicant or substance abuse preceding sexual activity, underestimation of personal risk, perception that
612 precautionary changes are not an accepted peer norm, limited perceived self-efficacy for success in
613 change efforts, high reinforcement value associated with frequent unsafe practices (e.g., a negative HIV
614 test result in the face of clear HIV risk behaviors), and a perception that vulnerability is associated with
615 “luck” or “fate” (79-82).

616 **Clarify important misconceptions about HIV transmission risks.** The counselor should address any
617 misconceptions about HIV transmission that arise in the client’s discussion of personal risk. For example,
618 as applicable, the counselor can clarify for the client that oral sex is not a risk-free behavior or that HIV
619 can be transmitted through the “cooker, cotton, or water” used by several persons sharing drugs and
620 discuss lower-risk alternatives (68). For HIV-infected clients, the counselor should discuss HIV
621 transmission risks associated with specific sexual or drug-use activities, even those in which the client
622 may not currently be engaged. However, for most clients, the counselor should focus on reducing clients’
623 current risks and avoid lengthy, global discussion about HIV transmission modes and the meaning of the
624 HIV test results, as this information can be more efficiently provided in other ways (see 3.3).

625 **Negotiate one concrete, achievable behavior change step that will reduce HIV risk.** Although the
626 optimal goal may be to entirely eliminate HIV risk behaviors, even small behavior changes can reduce the
627 probability of acquiring or transmitting HIV. Behavioral risk reduction steps should be acceptable to the
628 client and appropriate to the client’s situation. For clients with several high-risk behaviors, the counselor
629 should help the client focus on reducing the most important risk that he or she is willing to commit to
630 changing. The step need not be entirely personal. For many people, knowledge of a partner’s recent
631 HIV status (and thus talking with the partner about getting an HIV test) may be more critical than
632 personal behavior changes. In any case, the step should be explicit and achievable rather than general
633 (Box 6). Identifying the barriers and facilitators to achieving a step, through interactive discussion, role-
634 play modeling, recognizing positive social supports, or other methods will enhance the likelihood of success
635 (83). Writing down the agreed-upon goal may be useful. *For clients with ongoing risk behaviors,*
636 *referral to additional prevention services is encouraged.*

637 **Acknowledge and provide support for positive steps that have already been made.** Exploring
638 previous risk-reduction efforts is essential for understanding the strengths and challenges faced by the
639 client in reducing risk. Support for positive steps already taken increases the client’s beliefs that he or she
640 can successfully perform further HIV risk-reduction steps. For some clients, agreeing to have an HIV
641 test is an important step in reducing risk (5,70).

642 **Seek flexibility in the prevention approach and counseling process.** Counselors should avoid a
643 “one size fits all” prevention message. Specific behaviors that are safe for one person may be risky for
644 another (84). For example, unprotected vaginal intercourse may be unsafe with anonymous partners
645 whose HIV status is unknown, but safe for uninfected persons in a mutually monogamous relationship.

646 The length of counseling sessions will vary depending on client risk and comfort (e.g., counseling
647 adolescents may require more time than adults).

648 **Provide skills-building exercises.** Depending on client needs, the counselor can model or ask the
649 client to demonstrate proper use of male latex condoms, by using different brands on a penis model;
650 proper use of female condoms, by using female anatomy pictures; cleaning injection equipment if clean
651 syringes are unavailable; communicating safer sex commitments to new sex partners; or other problem-
652 solving strategies (79,85-87).

653 **Be clear when providing test results.** Test results should be provided at the beginning of the posttest
654 session. Counselors should never ask clients to “guess” their test results. Technical information about the
655 test can be provided in a brochure or other means so that the session can focus on personal HIV risk
656 reduction. In-depth, technical discussions of the “window period” (see 3.3, the meaning of the test results)
657 should be avoided, as these may confuse clients and diffuse the importance of the HIV prevention
658 message. Counselors should be clear that negative test results do not mean no HIV risk and should work
659 with the client to reconsider ongoing HIV risk behaviors and the importance of taking steps to reduce
660 those risks. Clients with ongoing risk behaviors should not be given a false sense of the safety of those
661 behaviors (i.e., avoid statements such as “Whatever you were doing seems to be safe” or “Continue to do
662 whatever you are doing now”).

663 **Box 5. Examples of Directed vs. Open-Ended Questions**

664 **Directed questions that may not facilitate**
665 **client-centered HIV prevention counseling:**

666 Have you ever injected drugs?

667 Have you ever had sex with a man (bisexual man)?

668 Have you ever had sex when you were under the
669 influence of alcohol or drugs?

670 Do you (always) use condoms when you have sex?

671 Can you always use condoms when you have sex?

672 Can you always use clean syringe and works when
673 you inject?

Open-ended questions that facilitate client-
centered HIV prevention counseling:

What are you doing that you think many be putting you at risk for HIV infection?

What are the riskiest things that you are doing?

If you are HIV-infected, how do you think you may have become infected?

When was the last time that you put yourself at risk for HIV? What was happening then?

How often do you use drugs or alcohol?

How do drugs or alcohol influence your HIV risk?

How often do you use condoms when you have sex?

When/with whom do you have sex without a condom?
When with a condom?

What are you currently doing to protect yourself from HIV? How is that working?

How risky are your sex/needle-sharing partners? For example, have they been recently tested for HIV?

Tell me about specific situations when you have reduced your HIV risk. What was going on that made that possible?

674 **Box 6. Examples of Global vs. Specific Risk-Reduction Steps for HIV Prevention**
 675 **Counseling**

676 In HIV prevention counseling, counselors work with clients to commit to a specific risk-reduction step
 677 relevant to reducing the clients' own risk. The risk-reduction step should be a small, explicit, and
 678 achievable goal, as opposed to a global goal.

679 Global risk-reduction steps	Specific risk-reduction steps
680 Always use condoms.	Buy a condom tomorrow and try it on.
	Carry a condom next time I go out (e.g., to the bar/nightclub).
	Starting today, put condoms on the nightstand beside the bed.
	Starting tonight, require my partner to use a condom next time or I will not have vaginal (anal) sex.
681 Have fewer or less risky partners.	Stop seeing (specific partner) who is seeing other people.
	Break up with (specific partner) before getting together with someone new.
682 Have safer sex.	Talk honestly with (specific partner) about my HIV status and ask about his/her HIV status.
	Next time I'm out with friends and may have sex, avoid getting "high" on drugs or alcohol.
	Only kissing, etc., with (specific partner) until we both have an HIV test.
	Tomorrow, ask (specific partner) if he or she has had a recent HIV test and has been tested for other STDs.
683 Stop injecting drugs.	Obtain a clean syringe, clean works tomorrow so I have them before I use next time.

684 In addition to the above counseling components considered necessary in conducting high-quality
 685 counseling, many experts (Expert Panel, Atlanta, Georgia, February 1999) suggested that the following

686 elements be adopted:

687 **Return to the same counselor.** Consistency of the client and counselor relationship helps the client feel
688 secure, reduces misunderstanding, and promotes the likelihood of effective risk reduction. Effective
689 counseling models have tended to use the same counselor for all sessions. (See The Compendium of HIV
690 Prevention Interventions with Evidence of Effectiveness,
691 http://www.cdc.gov/nchstp/hiv_aids/pubs/hivcompendium.pdf)

692 **Use a written protocol** (a counselor's guide to conducting an effective session) (73,88).

693 **Ensure ongoing support of supervisors and administrators.** Supervisory support is essential for
694 effective prevention programs. Training in HIV counseling approaches that focus on personal risk
695 reduction is recommended for anyone supervising counselors. Staff appraisals should prioritize completion
696 of critical counseling components over simply professionalism and completion of paperwork.

697 **Avoid using counseling sessions as a time for data collection.** If required, paperwork should be
698 completed at the end of the counseling session or done by staff who are not counseling. Check-list risk
699 assessments driven by data collection forms are a detriment to effective counseling because they can
700 encourage even skilled counselors to use directed questions, limit eye contact, and miss critical verbal and
701 nonverbal cues. The relevance of any routinely collected data should be periodically assessed.

702 **Avoid providing extraneous excessive information.** An emphasis on providing information may
703 prompt counselors to miss critical HIV prevention opportunities and clients to lose interest. Discussion
704 about theoretical HIV risks (e.g., sex with a person who has hemophilia, needle exposures through
705 tattoos) tends to shift the focus of the counseling away from the client's actual HIV risk situations to
706 "comfortable" but irrelevant topics.

707 **3.4.5 Who Should Deliver Prevention Counseling?**

708 In any setting where HIV testing is provided, existing personnel can be effective counselors if they have
709 the desire and appropriate training and employ the essential counseling components (see 3.4.4) (5,72).
710 Advanced degrees or extensive experience are not necessary for effective HIV prevention counseling
711 (72). Training in counseling is available (see 3.4.3). In situations where primary health-care providers
712 (e.g., physicians) may not be able to provide prevention counseling, auxiliary health professionals trained
713 in HIV prevention counseling models may be more practical providers of this service.

714 Although peer counseling has been successful in certain situations (20), research does not support a clear
715 risk-reduction need or benefit to match clients with counselors on the basis of the same or similar
716 backgrounds, gender, ethnicity, age, or peer group for intervention efficacy (89-91). However, the
717 following skills and counselor characteristics have been identified by an expert panel (Atlanta, Georgia,
718 February 1999) as important for effective HIV prevention counseling:

- 719 • Completion of standard training courses in client-centered HIV prevention counseling or other
720 risk-reduction counseling models
- 721 • Belief that counseling can make a difference
- 722 • Genuine interest in the counseling process
- 723 • Active listening skills
- 724 • Ability to use open-ended rather than directed questions (Box 5)
- 725 • Ability and comfort with an interactive negotiating style rather than a persuasive approach
- 726 • Ability to engender a supportive atmosphere and build trust with the client
- 727 • Ability to maintain client confidentiality
- 728 • Interest in learning new counseling and skills-building techniques
- 729 • Being informed about specific HIV transmission risks (68)
- 730 • Comfort in discussing specific HIV risk activities (i.e., explicit sex or drug activities)
- 731 • Ability to remain focused on risk-reduction goals
- 732 • Being supportive of routine, periodic quality assurance measures (see 7.1)

733 **3.4.6 Additional Counseling Considerations in Special Situations**

734 **HIV prevention counseling in the following situations entails special considerations.**

735 **Health-care workers following an occupational exposure.** Although HIV infection following
736 occupational exposure occurs infrequently, health-care workers should be counseled after an occupational
737 exposure to use measures to prevent transmission during the follow-up period (see guidelines that address
738 acute occupational exposure) (55). HIV-exposed health-care workers should be advised to abstain from
739 sex or use condoms and to avoid pregnancy; not to donate blood, plasma, organs, tissue, or semen; and, if
740 the exposed health-care worker is breastfeeding, to consider discontinuation of breastfeeding, especially
741 following high-risk exposures (55). The worker should also be told about the rationale for postexposure
742 prophylaxis, the risk for occupationally acquired HIV infection due to the exposure, the limitations of
743 current knowledge of the efficacy of antiretroviral therapy when used as postexposure prophylaxis, the
744 toxicity of the drugs involved, and the need for postexposure follow-up (including HIV testing), regardless
745 of whether antiretroviral therapy is taken.

746 **Persons with a single, recent nonoccupational HIV exposure.** After a reported sexual, injecting
747 drug use, or other nonoccupational exposure to HIV (see guidelines that address acute nonoccupational
748 exposure) (56), health-care providers should provide their clients with referral to promptly initiate
749 evaluation, counseling, and follow-up services. Although early postexposure prophylaxis may reduce a

750 person's likelihood of becoming infected with HIV, the efficacy of early treatment in preventing new
751 infection after acute nonoccupational HIV exposure is still unclear.

752 **Sex or needle-sharing partners of HIV-infected persons.** Sex or needle-sharing partners of HIV-
753 infected persons should be encouraged to have HIV prevention counseling and testing. Partners who are
754 HIV-discordant (one person HIV-infected and one uninfected) should receive counseling aimed at
755 preventing HIV transmission from the infected to the uninfected partner, including explicit discussion and
756 clarification of any misconceptions about HIV transmission risks associated with specific sexual and/or
757 needle-sharing activities. In addition, many HIV discordant couples benefit from ongoing HIV prevention
758 counseling aimed at personal risk reduction or from couples counseling (33,92-94).

759 Little evidence exists to conclusively support or refute whether simultaneous infection with two or more
760 strains of HIV is likely to occur or, if it does, whether it is associated with more aggressive or resistant
761 disease (95). Experts remain divided on the value of recommending consistent condom use to prevent
762 HIV sequelae for mutually monogamous, HIV-infected partners.

763 **Persons with newly identified HIV infection.** For persons who have recently learned that they are
764 HIV-infected, the next 3 to 6 months are important for them to access medical and other support services,
765 which can help them obtain treatment for their infection and establish and maintain behavior changes that
766 reduce the likelihood of their transmitting the virus to others. HIV prevention counseling should receive
767 the same high priority as referral for medical care and counseling for sex and needle-sharing partners. As
768 part of HIV prevention counseling, counselors should explicitly discuss and clarify any misconceptions
769 about the HIV transmission risk associated with specific sexual and/or needle-sharing activities. For
770 sexually active clients who are not in mutually monogamous partnerships, counselors should also address
771 strategies to prevent other sexually transmitted or bloodborne infections (e.g, gonorrhea, syphilis,
772 chlamydia, herpes simplex virus, human herpes virus type 8 [the virus linked to Kaposi sarcoma], hepatitis
773 B virus, hepatitis C virus, cytomegalovirus). A follow-up appointment after 3 to 6 months is recommended
774 by some experts (96) to assess whether clients were able to initiate medical care, minimize transmission
775 risks to uninfected partners, and access other needed services such as partner counseling and referral.
776 See guidance on partner counseling and referral (33) and prevention case management (34).

777 **Persons seeking repeat HIV testing.** In addition to brief prevention counseling sessions, ongoing HIV
778 prevention counseling aimed at personal risk reduction may be useful for persons seeking repeated HIV
779 testing who have continued HIV risk. Because repeated testing in the absence of other behavior changes
780 is an ineffective personal risk-reduction strategy, clients should be encouraged to explore alternative
781 prevention strategies and helped to identify and commit to additional risk-reduction steps. Clients with
782 ongoing risk behaviors may benefit from referral to other HIV prevention services, as they may be
783 experiencing reinforcement of their current risky behavior through repeated negative HIV test results or
784 viewing an HIV test as protective (97). See also 4.9.3 and guidance on prevention case management
785 (34).

786 **Persons with indeterminate HIV test results.** Until follow-up test results are available, persons with
787 an indeterminate test result should be provided information about the meaning of the test results (see
788 4.7.3). However, HIV prevention counseling should be approached in the same manner as for a person
789 with newly identified HIV infection (see above). Behaviors that minimize the risk for HIV transmission to
790 sex and needle-sharing partners should be emphasized, even if the client reports no risk behaviors. Clients
791 with repeated indeterminate test results at least 1 month apart are not HIV-infected and can be counseled
792 in the same way as clients with negative test results, unless recent HIV exposure is suspected (see 4.7.3).

793 **Persons who use drugs.** Persons who inject or use illicit drugs in other ways may be at increased risk
794 for acquiring HIV through unprotected sex with an HIV-infected partner (98-100). For injection drug
795 users, intervention studies suggest that personalized, interactive prevention counseling models using goal-
796 setting strategies may be effective in reducing both injecting drug and sexual risk behaviors (24-26,77). In
797 addition, mounting evidence supports the efficacy of community strategies such as methadone
798 maintenance programs, outreach programs, and syringe exchange in reducing new HIV infections among
799 injection drug users (101-105). Experts advocate recommending such strategies, in addition to individual
800 HIV prevention counseling, to persons who inject drugs.

801 **3.4.7 Addressing Barriers to HIV Prevention Counseling**

802 Several factors may prevent provision of high-quality HIV prevention counseling for clients at increased
803 HIV risk, such as unavailability of trained prevention counselors on site at the HIV test facility, client
804 reluctance, and low rates of client return for test results. Recommended strategies for addressing these
805 common barriers are to provide counseling services on site rather than referring clients for counseling
806 services, enhance client acceptance of counseling through examination and improvement of services, and
807 consider the use of alternate methods of providing counseling.

- 808 • **Provide On-Site Counseling**

809 Cost, lack, or turnover of trained staff and space constraints are barriers to providing
810 HIV prevention counseling services (106). However, given the proven efficacy of
811 prevention counseling models, in settings where HIV prevalence or frequency of HIV
812 risk behaviors among clients is higher (e.g., some primary care or emergency room
813 settings), the ability to provide such counseling on site is a high priority. Efforts should be
814 made to address and remove barriers to providing HIV prevention counseling on site.
815 Health educators or other auxiliary staff trained to discuss preventive services such as
816 healthy eating, prenatal education, or smoking cessation could, if adequately trained, be
817 effective HIV prevention counselors. In the interim, alternative resources should be
818 identified, and clearly defined referral systems should be arranged to settings that can

819 provide high-quality prevention counseling for clients at increased HIV risk. Systems to
820 ensure that referrals are completed should be established (see Section 5). Until
821 prevention counseling can be provided on site, an alternative such as home sample
822 collection, in which test results and counseling are available by telephone, may be
823 considered.

824 • **Enhance Client Acceptance of HIV Prevention Counseling**

825 Clients who agree to HIV testing and who decline HIV counseling often report they lack
826 time or already know about HIV transmission modes. However, counseling experts
827 assert that a major reason that counseling is refused is that clients do not perceive the
828 service to be personally useful. Most clients agreeing to an HIV test are concerned
829 about a specific risk and are willing to explore their personal risks. In settings where
830 many clients decline counseling, the type of counseling being provided, the manner in
831 which counseling is recommended, and the setting should be examined. Counseling may
832 provide information only and may not address clients' personal risk. The setting may
833 inhibit honest and open discussion of risk. Counselors may not offer services that are
834 linguistically, culturally, gender-, or age-appropriate. Counseling skills (e.g., attentive
835 listening, use of open-ended questions) that allow clients to participate may have been
836 overlooked. Even when a client at increased risk refuses counseling, use of one or two
837 open-ended questions that urge the client to examine his or her personal situation may
838 begin the process of personal exploration of risk (e.g., "What were your concerns that led
839 you to decide to get tested today?").

840 • **Consider the Use of Alternative Methods to Provide HIV Prevention Counseling**

841 Proven-effective HIV prevention counseling models thus far have used face-to-face
842 (individual or group) encounters between counselor and client and have involved at least
843 two brief sessions; face-to-face prevention counseling is still preferred for clients at
844 increased HIV risk. At this time, most HIV test sites use an enzyme immunoassay (EIA)
845 and a confirmatory test algorithm that requires several days for final test results. The
846 return visit for the test result offers an opportunity to continue prevention counseling in a
847 second, face-to-face meeting. However, in some settings (e.g., STD clinics, managed
848 care organizations, and other private settings), clients do not return for their results (107-
849 110). In such settings, counseling programs may elect to adopt strategies that increase
850 clients' receipt of their test results, and counseling strategies may need to be adapted
851 (111).

852 **Telephone counseling.** Limited studies among lower-risk STD clinic clients indicate
853 that substantially more clients learn their HIV infection status when negative test results
854 are provided by telephone rather than in person (13,112). Although home sample
855 collection provides a precedent for providing counseling by telephone to persons with
856 either negative or positive HIV test results, the efficacy of telephone counseling in
857 reducing HIV risk behaviors or number of new HIV infections has not been
858 demonstrated. In addition, at least one study suggests that telephone notification of
859 positive results is associated with delay in linkage to care (113). However, not learning
860 positive test results at all is a guaranteed “delay” in linkage to care. Many experts
861 recommend that provision of HIV test results and prevention counseling by telephone be
862 limited to clients whose results are negative (Expert Panel Meeting, Atlanta, Georgia,
863 February 1999). In addition, given the known risk-reduction benefits of face-to-face
864 counseling and lack of efficacy data on telephone counseling, these experts recommend
865 limiting telephone counseling to clients without known ongoing HIV risk behaviors (e.g.,
866 unprotected sex or needle-sharing with an HIV-infected [or status unknown] partner).
867 See also 4.8.1.

868 **Single-session prevention counseling with rapid testing.** Rapid tests, which are
869 increasingly being adopted, allow clients to receive their HIV test results on the same day
870 the test is done (see 4.6 and 4.8.2). This process could reduce the number of clients
871 receiving two prevention counseling sessions. Studies of the efficacy of single HIV
872 prevention counseling sessions for use with a rapid test are under way. Some single-
873 session counseling protocols have been successfully implemented in busy clinics and are
874 well accepted by most clients; however, how well a single counseling session reduces
875 risky behaviors or number of new HIV infections is unknown. For one counseling
876 protocol developed for use with a rapid test and currently under study, see
877 www.cdc.gov/hiv/projects/respect-2 . For clients with identified risk behaviors, referral or
878 rescheduling for return for ongoing counseling should be considered.

879 **3.4.8 Ensuring High-Quality HIV Prevention Counseling**

880 **Routine, periodic assessments should be conducted by all providers of counseling, testing, and**
881 **referral services to ensure that the counseling being conducted includes the recommended,**
882 **essential counseling elements.**

883 Experts concur that routine quality assurance is essential for high-quality HIV prevention counseling and

884 should always be done regardless of who offers the counseling or where the counseling occurs (Expert
885 Panel Meeting, Atlanta, Georgia, February 1999). High-quality counseling requires that supervisors are
886 aware of HIV prevention counseling goals and necessary counselor skills. Supervisor and administrator
887 support of HIV counseling models focused on personal risk reduction (distinct from information
888 dissemination) is critical to provision of effective services.

889 Quality assurance for counseling optimally contains the following elements:

890

891 • **Training and Continuing Education.** Basic training in the use of one or more of the interactive
892 HIV prevention counseling models aimed at personal risk reduction is recommended for
893 counselors and supervisors. In addition, counselors may benefit from formal training about
894 transmission and prevention of HIV and other sexually transmitted and bloodborne diseases, the
895 natural history of HIV, recognition and treatment of opportunistic infections, new therapeutic
896 agents used to treat HIV and AIDS, partner counseling and referral services, prevention case
897 management, and other HIV prevention services available in their community (e.g., regarding
898 substance abuse assessment, cultural competence, adolescent issues, domestic abuse, health
899 concerns for gay or lesbian clients). Additional training in specific counseling skills is also
900 warranted. For example, counselors conducting group sessions can benefit from training in
901 facilitating groups. For training opportunities, providers or supervisors can contact their state HIV
902 office.

903 • **Supervisor Observation and Immediate Feedback to Counselors.** Direct observation of
904 counseling sessions can help ensure that counseling objectives are being met (72). This may be
905 done periodically by a supervisor (after first obtaining client consent). Sessions may also be
906 audio-taped (after first obtaining client consent), or counseling can be demonstrated through role-
907 play scenarios between the counselor and supervisor. Observation and feedback should be
908 structured, and the outcome should be constructive rather than punitive. Supervisors should
909 support positive elements of the prevention counseling session and provide specific, constructive
910 comments about content areas that could be improved. Observation and feedback should be
911 conducted on a regular basis as part of “routine” counseling. Staff discomfort with observation
912 typically wanes over time; many counselors find the sessions useful in enhancing skills. When
913 observation is presented as a matter of routine course, clients seldom refuse to participate. A
914 suggested time frame for routine, direct observation of an HIV prevention counselor by the
915 supervisor is twice monthly for the first 6 months of performing HIV counseling services, monthly
916 for the second 6 months, and quarterly for counselors with more than one year of experience.

917 After observation, supervisors should provide feedback to counselors quickly, preferably during
918 the same week. Templates of observation and feedback forms that have been used in research
919 studies of client-centered HIV prevention counseling can be obtained at
920 www.cdc.gov/nchstp/hiv_aids/projects/RESPECT and www.cdc.gov/hiv/projects/respect-2.

921 • **Periodic Evaluation of Physical Space, Client Flow, and Time Issues.** Counseling sessions
922 should be done in a private space where discussion cannot be overheard. Optimally, clients
923 should not wait for long periods between testing and counseling. Any waiting times could be used
924 for information dissemination through videos or other means. Periodic time-flow analyses or
925 client surveys can be used to evaluate adequacy of space and client flow and whether waiting
926 periods are excessive.

927 • **Periodic Counselor and/or Client Satisfaction Evaluations.** Evaluations of client satisfaction
928 can ensure that services meet client needs. In addition, these evaluations can provide important
929 feedback to counselors who otherwise may not see the benefits of what they do. Evaluations can
930 be brief. However, surveys should optimally address whether specific counseling goals were met,
931 for example, the type of interaction (e.g., “Who talked more, the counselor or the client?”), and,
932 when applicable, specifics of development of the risk-reduction plan (e.g., “What was the behavior
933 change step that you agreed to work on?”). Methods that allow linking of client and counselor
934 descriptions of a particular session may be useful. Conducting such evaluations only occasionally
935 (e.g., for one or two weeks once or twice a year) decreases the programmatic burden and is
936 probably sufficient to identify problems. Program evaluation of overall counseling, testing, and
937 referral services is described in Section 7.0.

938 • **Case Conferences.** Regularly scheduled meetings of counselors allow supervisors to understand
939 counselors’ skills and areas for improvement and can help counselors learn techniques from their
940 colleagues. Case conferences are an opportunity for counselors to bring up questions being asked
941 by clients so that providers are better aware of the issues facing those at increased risk or those
942 HIV-infected in their facility. Some programs report case conferences help with counselor
943 fatigue and “burn out” by providing a positive outlet for dealing with difficult situations. Discussion
944 may focus on a full session with a hard-to-address client or only on simple components (e.g.,
945 developing an acceptable and practical risk-reduction plan with a client who denies the magnitude
946 of his or her HIV risks). Frequency of case conferences should be balanced with client volume,
947 with efforts made to meet, at a minimum, on a monthly basis.

948 **4.0 HIV Testing**

949 **4.1 Background**

950 During the past decade, the demonstrated medical benefits of antiretroviral therapy have underscored the
951 importance of expanding voluntary HIV testing services to facilitate early diagnosis and treatment of
952 HIV-infected persons. Early knowledge of HIV infection can also result in public health benefits by
953 decreasing risk behaviors that could transmit HIV to uninfected persons (152). Uninfected persons may
954 benefit from HIV testing if knowing their HIV status assists them in modifying or reducing risk behavior.
955 In particular, knowledge of both one's own HIV status and one's partner's HIV status may be the most
956 critically important factor for preventing acquisition of HIV (114).

957 The past decade has seen a marked expansion in the array of HIV test technologies. In addition to
958 venipuncture, specimens can be collected for HIV testing through U.S. Food and Drug Administration
959 (FDA)-approved oral fluid, urine, and finger-stick methods (31). These methods can help simplify testing
960 procedures and may increase the proportion of clients at increased risk who accept HIV testing. The
961 availability of rapid HIV testing permits test results to be provided to clients at the time of testing (see
962 4.8.2) and is particularly useful in settings where clients do not routinely return for their HIV test results
963 and follow-up is difficult (115). HIV testing may also be conducted using commercially available, FDA-
964 approved home sample collection devices, for which HIV test results are available to clients by telephone
965 after a blood specimen collected by the client is sent to a laboratory for testing (43)(see 4.6, Table).

966 The decision to adopt a particular test technology in a clinic or nonclinic setting should be based on several
967 factors, including accuracy of the test, client preferences and acceptability, likelihood of client receiving
968 test results, cost and mechanism for provider reimbursement, ease of sample collection, complexity of
969 laboratory services required for the test, availability of trained personnel, and FDA licensure of the test.

970 **4.2 Goals**

971 HIV testing seeks to

- 972 • Ensure early knowledge of HIV infection status among HIV-infected persons
- 973 • Ensure knowledge of HIV infection status among persons at increased risk for HIV infection

974 **4.3 Who Should Offer Testing?**

975 **Health-care providers in a wide variety of settings should offer voluntary HIV testing with**
976 **informed consent to clients at increased risk for HIV infection.**

977 Given the medical and public health benefits of early HIV diagnosis (116), health-care providers in a wide
978 variety of settings (Box 1) should offer voluntary HIV testing services to clients at risk for HIV infection,
979 either on site or through referral to other providers.

980 The decision to offer HIV testing is facilitated when the provider believes that testing is beneficial to
981 clients for early diagnosis and prevention purposes (106). The decision is also influenced by constraints on
982 finances, time, and other resources. Providers who serve clients at increased risk for HIV infection but
983 who have limited capacity for offering counseling and testing services should maintain clear and
984 appropriate methods of referral to services elsewhere (see section 5). To optimize client referral,
985 providers who do offer HIV counseling and testing services should establish collaborative relationships
986 with providers serving populations at increased risk for HIV who may not offer such services.

987 **4.4 Who Should Be Tested?**

988 **Routine voluntary HIV testing is recommended for all clients in settings where the client**
989 **population is generally at increased behavioral risk for HIV infection, regardless of setting HIV**
990 **prevalence. Routine voluntary HIV testing is recommended for most clients in settings where**
991 **HIV prevalence is high (e.g., $\geq 1\%$, see 2.5). Routine voluntary HIV testing is also**
992 **recommended for all pregnant women because treatment is available for prevention of perinatal**
993 **transmission (30).**

994 **Targeted voluntary HIV testing is recommended for clients in settings where both HIV**
995 **prevalence is low (see 2.5.5) and where the client population is not at increased behavioral risk**
996 **for HIV infection. Results of risk screening (2.5.6) can be used to determine which clients**
997 **should be recommended HIV testing.**

998
999 The decision to routinely recommend voluntary HIV testing to most or all clients within a setting or to
1000 target HIV testing to selected clients at increased risk for HIV infection on the basis of risk screening

1001 should be based on setting HIV prevalence, behavioral HIV risk of the client population, and the
1002 availability of potentially beneficial treatments to prevent HIV infection (e.g., prevention of perinatal HIV
1003 transmission)(30). See 2.5.

1004 Numerous studies have shown that targeting testing on the basis of self-reported risk factors is not fully
1005 effective at identifying HIV-infected clients in settings with high HIV prevalence and settings serving
1006 client populations at increased behavioral risk for HIV infection (45-53). Targeted testing may also fail to
1007 identify all HIV-infected women who could benefit from treatment to prevent perinatal HIV transmission
1008 (117-121).

1009 Routine voluntary testing should thus be recommended to most or all clients in these settings. Targeted
1010 testing, however, may be more feasible and cost-effective for identifying small numbers of HIV-infected
1011 clients in low-prevalence populations where most clients have minimal risk (54). Regardless of reported or
1012 suspected risk in the settings, any client who requests HIV testing should be offered a test to provide
1013 knowledge of HIV status.

1014 **4.5 Addressing Barriers to HIV Testing**

1015 **HIV testing should be made as convenient as possible to facilitate client knowledge of HIV**
1016 **infection status.**

1017 Reasonable effort should be made to remove or lower barriers to HIV testing services by addressing
1018 accessibility and availability; responsiveness to client and community needs and priorities; convenience to
1019 client; client preferences; availability of anonymous HIV testing in addition to confidential HIV testing;
1020 cultural, linguistic, gender, and age appropriateness; and confidentiality, safety, and privacy (see 2.4).

1021 Providers can facilitate client acceptance of HIV testing by providing an environment that is supportive of
1022 anonymous as well as confidential testing and that allows clients to conveniently obtain HIV prevention
1023 counseling and testing, HIV test results, and referral to medical and other supportive services.

1024 HIV testing is more likely to be accepted when clients perceive their own HIV risk and acknowledge
1025 behaviors placing them at increased risk for HIV (122); voluntary testing is routinely offered to clients
1026 rather than relying on client request (106,123); protections for client confidentiality are in place (106,124);
1027 anonymous testing is made available (106,125); alternate HIV test technologies are offered to clients (32);

1028 providers recommend testing as part of appropriate medical care (126,127); and both providers (128) and
1029 clients (106) perceive HIV counseling and testing to be beneficial.

1030 Acceptance of HIV testing has been shown to be lower when clients have previously been tested and
1031 when clients have fears about coping with their test results (95,106).

1032 **4.6 Laboratory Characteristics of HIV Test Technologies**

1033 **Only FDA-approved HIV tests should be used for diagnostic purposes.**

1034 **Routine screening in the United States for HIV-2 and HIV-1 group O infections is not generally**
1035 **recommended for diagnostic testing.**

1036 A variety of HIV test technologies have been approved by the FDA for diagnostic use in the United
1037 States. These tests enable testing of different fluids: whole blood, serum, plasma, oral fluid, and urine
1038 (Table).

1039 Available FDA-approved HIV test technologies

- 1040 • Enable specimen collection procedures that are less invasive than venipuncture, thus permitting
1041 expansion of HIV testing services into nontraditional settings, such as outreach and community
1042 settings (with collection of urine and oral fluids, collection of specimens by finger stick) (31)
- 1043 • Enable provision of HIV test results during a single clinic visit at the time of testing (with rapid
1044 HIV tests) (115)
- 1045 • Increase the convenience of HIV testing without requiring a clinic visit for testing or receipt of
1046 test results (with home sample collection tests) (43).

1047 **Home testing vs. home sample collection.** Home-use HIV test kits, in which a consumer purchases a
1048 test kit, collects a sample in private, and interprets his or her own HIV test results in a few minutes, have
1049 not been approved by the FDA. These tests must be distinguished from FDA-approved home sample
1050 collection kits, in which a consumer purchases a test kit, collects a sample in private, sends the sample to
1051 a laboratory for testing, and telephones for his or her HIV test result, counseling, and referral. The
1052 Federal Trade Commission has recently warned that some home-use HIV test kits, many of which are

1053 available on the Internet and in the “gray” market, supply inaccurate results and are not FDA-approved
1054 (129).

1055 **HIV-2 and HIV-1 group O infections.** Although most HIV infections in the United States are of HIV-
1056 1 group B subtype, currently approved EIA tests can accurately identify infections with nearly all non-B
1057 strains and many infections with group O HIV strains (130). Infections with HIV type 2 (HIV-2) and
1058 HIV-1 group O remain very rare in the United States (131,132), and routine screening for these strains is
1059 not generally recommended as part of diagnostic testing except in areas where many such infections
1060 have been identified. Routine screening for HIV-2 may be appropriate in some populations where
1061 potential risk of HIV-2 infection is higher (133). The FDA has recommended routine screening for
1062 antibody to HIV-2 since June 1992 (in addition to HIV-1) for all donations made to blood centers (133).
1063 Clients who have clinical, epidemiologic, or laboratory history that suggests HIV infection and negative,
1064 indeterminate, or inconclusive HIV-1 screening tests should receive further diagnostic testing to rule out
1065 HIV infection (130), potentially including testing for HIV-1 non-B (130) and HIV-2 strains (133).

1066 **Other test uses.** Test technologies may receive approval from the FDA for purposes other than
1067 diagnostic use. For example, FDA-approved viral load and HIV-1 p24 antigen assays are not intended for
1068 routine diagnostic use but may be used in clinical management of HIV-infected persons in conjunction
1069 with clinical signs and symptoms and other laboratory markers of disease progression. The HIV-1 p24
1070 antigen assays have been approved for routine screening in blood and plasma centers and as an aid in
1071 diagnosis or prognosis monitoring; however, routine use of HIV-1 p24 assays for diagnosis of HIV
1072 infection in other settings has been discouraged because of the relatively low sensitivity and specificity of
1073 the assay when used alone (134).

1074 Table. Performance Attributes and Potential Applications of FDA-Approved HIV Test Technologies

	Serum-based EIA	Rapid EIA or other rapid method	Home sample collection^a	Oral fluid	Urine-based assay
1075 Specimen	Serum or plasma	Serum, plasma, whole blood	Dried blood spot	Oral mucosal transudate	Urine
1076 Mode of collection 1077	Phlebotomy	Phlebotomy, finger stick	Finger stick	Oral fluid collection device	Urine cup
1078 CLIA test categorization 1079	High complexity	Moderate complexity ^b	Collection—not CLIA applicable Testing—high complexity	Collection—not CLIA applicable Testing—high complexity	Collection—not CLIA applicable Testing—high complexity
1080 FDA-approved: 1081 Screening test 1082 Confirmatory test	EIA Western blot/IFA	Rapid EIA Western blot/IFA ^c	EIA Western blot/IFA	EIA Western blot	Urine EIA Urine Western blot
1083 Licensure approval ^d 1084	HIV 1/2 ^e	HIV-1	HIV-1	HIV-1	HIV-1

1085 1086	Provision of results	<p>HIV(-): Test result at return visit (typically a few days to 1-2 weeks)</p> <p>HIV(+): Confirmed result at return visit</p>	<p>HIV(-): Test result at time of testing (typically 30-60 minutes)</p> <p>HIV(+): Preliminary positive test result at time of testing;^f confirmed result at return visit</p>	<p>HIV(-): Test result when client telephones (typically 3-7 days)</p> <p>HIV(+): Confirmed result by telephone</p>	<p>HIV(-): Test result at return visit (typically 1-2 weeks)</p> <p>HIV(+): Confirmed result at return visit</p>	<p>HIV(-): Test result at return visit (typically 1-2 weeks)</p> <p>HIV(+): Test result at return visit; requires further confirmation on blood sample because of lower specificity of urine Western blot in comparison with serum-based Western blot/IFA</p>
--------------	----------------------	--	--	---	--	---

1087	Advantages	<ul style="list-style-type: none"> • High sensitivity • Rare false-positives • High-volume processing • Utility for testing for other conditions (e.g., STDs) 	<ul style="list-style-type: none"> • Convenience • Increased receipt of test results • Use in urgent medical circumstances (e.g., postexposure prophylaxis) 	<ul style="list-style-type: none"> • Convenience • Anonymity • Privacy • Conservation of public resources 	<ul style="list-style-type: none"> • Noninvasiveness • Nontechnical collection • No venipuncture • Decreased infectious hazard • Utility in nonclinical settings 	<ul style="list-style-type: none"> • Noninvasiveness • Nontechnical collection • No venipuncture • Decreased infectious hazard • Utility in nonclinical settings • Utility for testing for other conditions (e.g., STDs)
1088	Potential settings	<ul style="list-style-type: none"> • Blood screening • Wide variety of health-care settings and client populations 	<ul style="list-style-type: none"> • Clinics with low return rates • Perinatal/labor and delivery for prophylaxis • Health-care settings for decisions about postexposure prophylaxis • Rapid EIA requires on-site laboratory testing capability; other rapid tests may not 	<ul style="list-style-type: none"> • Outreach settings • Community-based settings • Syringe exchange programs • Rural areas • Clinics with low-risk populations • Home 	<ul style="list-style-type: none"> • Outreach settings • Community-based settings • Syringe exchange programs • Drug treatment centers 	<ul style="list-style-type: none"> • Outreach settings • Community-based settings • Syringe exchange programs • Drug treatment centers

1089 ^a Home sample collection should be distinguished from home use testing. While home sample collection has been approved by the FDA, no home HIV tests have

1090 received approval or licensing by the FDA (31).

1091 ^b Currently, there is only one licensed rapid test (SUDS) that is classified as a moderate complexity test under CLIA. Rapid tests that are FDA-licensed in the future

1092 may receive different CLIA classifications (e.g., low complexity) depending on the expertise required to perform the test correctly and consistently. All other HIV

1093 tests are classified as high complexity.

1094 ^c As of June 2000, only one rapid test (SUDS) has been licensed for use; however, in the future, a rapid test may be able to
1095 be confirmed with a second rapid test to provide high sensitivity, specificity, and predictive value comparable to
1096 EIA/Western blot and an immediate test result (135).

1097 ^d While current tests detect most HIV-1 group O infections, few tests detect all HIV-1 group O infections.

1098 ^e All serum EIAs in use for diagnostic screening detect HIV-1, but not all detect HIV-2. EIAs detecting HIV-1 and -2 are
1099 required only for blood screening and are recommended only in clinical circumstances where HIV-2 infection is likely.

1100 ^f See language for provision of “preliminary” positive test results from a single rapid test (115).


1101 FDA, U.S. Food and Drug Administration; EIA, enzyme immunoassay; CLIA, Clinical Laboratory Improvement

1102 Amendments; IFA, immunofluorescence assay.

1103 **4.7 Interpreting HIV Test Results**

1104 **Standard algorithm** (Figure 4). HIV-1 testing consists of initial screening with an FDA-licensed EIA to
1105 detect antibodies to HIV. Specimens with a nonreactive result from the initial EIA are considered HIV-
1106 negative unless recent exposure has been documented (see 4.7.2). Specimens with a reactive EIA result
1107 are retested in duplicate. If the result of either duplicate test is reactive, the specimen is reported as
1108 repeatedly reactive and undergoes confirmatory testing with a more specific FDA-licensed supplemental
1109 test such as a Western blot or, less commonly, an immunofluorescence assay (IFA). Only specimens that
1110 are repeatedly reactive by EIA and IFA-positive or Western blot-reactive are considered HIV-positive
1111 and indicative of HIV infection. Repeatedly EIA-reactive specimens occasionally provide an
1112 indeterminate Western blot result, which may represent either an incomplete antibody response to HIV in
1113 sera from infected persons or nonspecific reactions in sera from uninfected persons (136). Although IFA
1114 can be used to resolve an EIA-reactive Western blot indeterminate sample, this assay is not widely
1115 available. It is recommended that a second specimen from persons with indeterminate Western blot
1116 results be collected at least 1 month later and retested (see 4.7.3).

1117 **Figure 4.** The HIV-1 testing algorithm. In settings or for clients where HIV-2 is of concern, persons with
1118 a negative or indeterminate confirmatory test could be screened for HIV-2 using the same algorithm.
1119 Modified from the figure presented by the Association of State and Territorial Public
1120 Health Directors, Eighth Annual Conference on Human Retrovirus Testing, 1993.



1140 *An IFA can be used to resolve an indeterminate Western blot result; however, since IFAs are not widely
1141 available, a follow-up specimen should be collected at least one month after the initial indeterminate Western blot

1142 and retested.

1143 Modified testing algorithms are anticipated with the FDA approval of additional rapid HIV tests. If two or more
1144 sensitive and specific rapid HIV tests became available, one positive rapid test could be confirmed with a second
1145 different rapid test. This combination has been demonstrated to provide positive predictive value comparable to the
1146 EIA/Western blot or IFA algorithm above (135). However, at the time of publication of these guidelines, no such
1147 algorithms have been adequately assessed for use in the United States.

1148 **4.7.1 Positive HIV Test Results**

1149 An HIV test should be considered positive only after both screening and confirmatory tests are positive. A
1150 confirmed positive test result indicates that a person has been infected with HIV. False-positive results under these
1151 testing circumstances are extremely rare. However, the possibility of a mislabeled sample or laboratory error must
1152 be considered, especially for a client with no identifiable risk for HIV infection. HIV vaccine-induced antibodies
1153 may also be detected by current HIV tests and may result in a false-positive test. Persons participating in vaccine
1154 trials who desire HIV testing should identify themselves as being in such trials and should be referred to study
1155 investigators at their trial site for HIV testing services.

1156 **4.7.2 Negative HIV Test Results**

1157 A negative test result usually indicates that a person is not infected. With earlier tests using whole virus-lysate
1158 EIAs, the estimated median time between exposure and HIV antibody seroconversion was 2.4 months (137). With
1159 newer, more sensitive HIV antibody tests, detection of HIV antibody is approximately 20 days earlier than with
1160 whole virus lysate EIA (138). Consequently, most infected persons will develop detectable HIV antibody by 3
1161 months after exposure.

1162 Because is it likely that a negative test truly indicates absence of infection (high predictive value negative), a
1163 negative test should seldom be repeated in clients in settings with low HIV prevalence. For clients with a recent
1164 history of known or possible exposure to HIV who are tested before they develop detectable antibodies, the
1165 possibility of HIV infection cannot be definitively excluded without follow-up HIV testing (35)(see 4.9). In
1166 addition, a false-negative test result should be considered in persons with a negative HIV-1 test who have clinical
1167 symptoms suggestive of HIV infection or AIDS. Additional testing for HIV-2 and HIV-1 group O infections may
1168 be appropriate for these persons.

1170 **4.7.3 Indeterminate HIV Test Results**

1171 Almost all HIV-1-infected persons with initial indeterminate Western blot results will develop detectable HIV
1172 antibody within 1 month (136,139,140). Persons with an initial indeterminate Western blot result should be retested
1173 for HIV-1 infection at least 1 month later. Persons with continued indeterminate Western blot results after 1 month
1174 are highly unlikely to be HIV-infected and should be counseled as though they are not HIV-infected, unless recent

1175 HIV exposure is suspected. The use of viral DNA/RNA assays is not generally recommended to resolve
1176 indeterminate test results since these assays have not been approved by FDA for diagnostic use; however, in
1177 consultation with clinical and laboratory experts, such testing could be considered.

1178 **4.7.4 Inconclusive HIV Test Results**

1179 Some HIV tests will result in inconclusive results because of insufficient quantity of specimen for the screening or
1180 confirmatory tests. Positive rapid tests should be considered preliminary until confirmatory tests have been
1181 completed.

1182

1183 **4.8 Informing Clients of Test Results**

1184

1185 **Providers should take responsibility for ensuring that HIV test results are given to clients. This is**
1186 **particularly important for HIV-infected clients.**

1187

1188 **The adoption of new HIV test technologies and alternative methods of providing HIV-negative test**
1189 **results should be considered when face-to-face rates of return for test results are low. Strict**
1190 **confidentiality of both the receipt of the HIV test and the HIV test result must be maintained,**
1191 **regardless of the method used.**

1192 Because low rates of return for test results occur in many settings offering HIV counseling, testing, and referral
1193 services, providers should make strong efforts to ensure that clients tested for HIV infection receive their HIV test
1194 results, particularly HIV-infected clients who may benefit from earlier entry into care and initiation of antiretroviral
1195 therapy. A range of flexible approaches exists to maximize the number and proportion of persons tested for HIV
1196 who receive their test results in a timely manner. As necessary, providers should seek the support of their local or
1197 state health department for help in providing test results to clients.

1198 **4.8.1 Increasing Receipt of HIV Test Results**

1199 Because knowledge of HIV status is a critical HIV prevention strategy and essential for entry into care services,
1200 providers should stress to clients the importance of returning to receive the test results and establish a plan with the
1201 client for how he or she will obtain the results (see section 3.0). Reminder systems may be useful. Using alternate
1202 HIV test technologies may increase the percentage of tested persons who learn their HIV status.

1203 **Providing Test Results by Telephone.** Many clinicians routinely notify clients of negative test results for

1204 various diseases and conditions by means other than face-to-face (e.g., telephone) and request clients to return to
1205 the clinic to discuss positive test results that may indicate potential life-threatening illnesses. This strategy can also
1206 be applied, under certain circumstances, to notify clients of their HIV test results. Face-to-face provision of HIV
1207 test results is strongly encouraged for HIV-infected clients and HIV-uninfected clients at increased risk who may
1208 benefit from HIV prevention counseling and referral to outside sources of care (see also 3.4.7). It may be
1209 appropriate to provide HIV-uninfected clients not at increased risk the option of receiving HIV test results and
1210 counseling by telephone—with the understanding that assurance of client confidentiality is paramount. Limited
1211 research suggests that offering clients the option of contacting the provider by telephone to receive negative HIV
1212 results may increase rates of receipt of test results, satisfy client preferences for options, and preserve clinic
1213 resources without apparent adverse consequences (43,112). No published research exists regarding the use of
1214 telephones for providing positive HIV test results with most HIV test technologies. There is very limited
1215 experience regarding the use of telephones in providing HIV-positive test results with home sample collection
1216 testing (43).

1217

1218 **4.8.2 Current Considerations: Rapid Tests**

1219 During the initial visit, the provider can definitively tell a client who has had a single rapid HIV test with negative
1220 results that he or she is not infected (115) except where retesting may be indicated because of recent known or
1221 possible exposure to HIV (see 4.9). Pending confirmatory testing, the meaning of a reactive rapid HIV test result
1222 should be carefully communicated to the client to account for the possibility of a false-positive result.

1223 Since the likelihood that a positive screening test is truly positive (i.e., the client is truly infected with HIV)
1224 decreases as HIV prevalence in the tested population gets lower, false-positive HIV test results are more likely to
1225 occur in settings where the tested population prevalence is lower than in settings where the tested population
1226 prevalence is higher. When a preliminary positive rapid test is explained to clients, phrases such as "a good chance
1227 of being infected" or "very likely infected" can be used to indicate the likelihood of HIV infection and qualified on
1228 the basis of both the HIV prevalence in the setting and the client's individual risk (115, 153). Further testing is
1229 always required to confirm a reactive screening test result.

1230 **4.9 Subsequent Testing in HIV-Uninfected Clients**

1231 **The timing and frequency of subsequent HIV testing should be individualized to client needs.**

1232 A negative HIV test usually indicates the absence of HIV infection (35). Because very recent infection cannot be
1233 excluded without follow-up testing (see 4.7.2), the appropriate timing and frequency for offering follow-up testing

1234 has been an ongoing question. Although follow-up testing at 6 months after possible exposure has been
1235 recommended in the past (4), follow-up testing 6 months after possible exposure is not warranted for most clients
1236 who do not have recent HIV exposure.

1237 Providers should consider the factors below when recommending the timing and frequency for follow-up HIV
1238 testing:

- 1239 • Timing of the last potential exposure
- 1240 • Probability of HIV infection given type of exposure
- 1241 • Presence or likelihood of ongoing risk behavior
- 1242 • Likelihood of returning for follow-up HIV testing, prevention counseling, and referral
- 1243 • Client anxiety
- 1244 • Provider and client relationship
- 1245 • Availability of clinic resources

1246

1247 **4.9.1 Recent Exposure**

1248 Follow-up testing may be appropriate for clients who have negative test results but who have not had time to
1249 develop detectable antibody after a recent documented occupational (55) or nonoccupational (sexual or needle-
1250 sharing) (56) exposure to HIV-infected persons or to persons at increased risk for HIV with unknown serostatus.
1251 The timing of subsequent testing must address these issues: it should provide “reasonable” assurance that the
1252 exposure of concern did not lead to infection; and/or it should be done in a timely manner so that clients identified
1253 as HIV-infected can receive appropriate antiretroviral treatment and prevention services as soon as possible.

1254

1255

1256 **4.9.2 Single Possible or Known Exposure**

1257 For persons with a single exposure, the timing of the exposure should be determined. Most infected persons will
1258 have developed detectable HIV antibody within 3 months after exposure (134). If the initial test was negative,
1259 repeat testing should be considered at 3 months after exposure to account for the possibility of a false-negative
1260 test result. If the follow-up test is nonreactive, the client is very likely not HIV-infected. If the client was exposed
1261 to a known HIV-infected person or if provider and/or client concern remains, a second repeat test may be
1262 considered at or after 6 months from the exposure. Very rare cases of seroconversion between 6 and 12 months
1263 after known exposure have been reported (141). Extended follow-up testing beyond 6 months after exposure to
1264 account for possible delayed seroconversion is not generally recommended and should be based on clinical
1265 judgment and individualized to the particular needs of the client (55).

1266 **4.9.3 Ongoing Exposure**

1267 Persons with continued HIV risk behavior pose a special challenge in regard to follow-up testing. In some settings,
1268 clients with ongoing risk represent a substantial proportion of the clinic population receiving HIV counseling, testing,
1269 and referral services. In most circumstances, follow-up HIV testing should be recommended periodically (e.g.,
1270 every 6 months) for clients with ongoing risk behavior to monitor the client's HIV status, but more importantly, to
1271 facilitate continued client contact, opportunities for HIV prevention counseling (see 3.4), and referral to additional
1272 prevention and support services.

1273 **4.9.4 No Identifiable Risk**

1274 In general, persons with no recent identifiable risk for HIV infection should be provided additional HIV prevention
1275 counseling (see 3.4) and follow-up testing, when requested. Efforts should be made to understand the reasons
1276 these clients are repeatedly seeking follow-up testing. These clients should be considered for in-depth prevention
1277 counseling and referral to outside sources of care, where appropriate.

1278 **4.9.5 Special Considerations**

1279 General recommendations for follow-up testing may not be applicable in all circumstances. In certain
1280 circumstances, e.g., when persons are simultaneously exposed to hepatitis C virus and HIV (55) and when persons
1281 have received HIV vaccines, guidance should be provided only with expert consultation (55).

1282 **4.10 Ensuring High-Quality Testing**

1283 Counseling, testing, and referral programs should coordinate activities with state and local laboratories to ensure
1284 high-quality HIV testing through proper specimen collection, storage, and transport. Laboratories performing HIV
1285 testing must be enrolled in proficiency testing programs and conduct activities in accordance with regulatory
1286 standards outlined by the Clinical Laboratory Improvement Amendments (CLIA) of 1988 (142). Currently,
1287 laboratory errors most often occur in the pre-analytic steps of testing (specimen collection, labeling, transporting,
1288 processing, and storing) and in the postanalytic steps of testing (results validation and reporting) (143-145).
1289

1290

5.0 Referral

1291

5.1 Background

1292

Referral is a key component of comprehensive HIV prevention services because not all providers can address the variety of medical, prevention, and psychosocial issues that influence a person's ability to initiate and sustain behavioral changes that reduce the risk of acquiring or transmitting HIV.

1293

1294

1295

Most published studies have addressed the effectiveness of referrals in the context of medical case management systems. Few published studies have evaluated the effectiveness of HIV-related referrals in the context of counseling and testing services. These guidelines have been developed on the basis of the scant published literature and expert opinion that identify characteristics, methods, and "best practices" likely to facilitate effective referrals.

1296

1297

1298

1299

5.2 Goals

1300

HIV referral seeks to

1301

- Ensure that HIV-infected persons have access to appropriate medical, prevention, and psychosocial support services

1302

1303

- Ensure that individuals at increased risk for HIV infection have access to appropriate medical, prevention, and psychosocial support services

1304

1305

1306

1307

5.3 Definition

1308

In the context of HIV prevention counseling and testing, referral is the process by which client needs for care and supportive services are assessed and prioritized. Clients are then provided with assistance (e.g., setting up appointments, providing transportation) in accessing services. Referral should also include reasonable follow-up efforts necessary to facilitate initial contact with care and support service providers.

1309

1310

1311

1312

When provided in the context of HIV prevention counseling and testing, referral does not include ongoing support or management of the referral. Referral is not intended to replace case management, which is generally characterized by an ongoing relationship with a client that includes comprehensive assessment of medical and psychosocial support needs, development of a formal plan to address needs, substantial assistance in accessing

1313

1314

1315

1316 referral services, and monitoring of service delivery.

1317 **5.4 Who Should Receive Referrals?**

1318 **Referral services should be offered to all clients who are HIV-infected or at increased risk for HIV.**

1319 For HIV-infected clients and those not infected but at increased risk for HIV, linkage with appropriate medical,
1320 prevention, and other supportive services increases the likelihood of maintaining health, enhancing longevity and
1321 quality of life, and reducing the risk of transmitting or acquiring HIV. Advances in medical treatment and
1322 prevention interventions underscore the critical and essential role that referral plays in efforts to decrease illness
1323 and death associated with HIV infection and AIDS.

1324 **5.5 Typical Referral Needs**

1325 **Clients should be referred to services that are responsive to their priority needs and that are culturally,**
1326 **linguistically, gender-, and age-appropriate.**

1327 • **Medical Evaluation, Care, and Treatment**

1328 HIV-infected clients should receive or be referred to medical services that address their HIV infection,
1329 including treatment or prevention of opportunistic infections and evaluation of immune system function.
1330 Prophylaxis for opportunistic infections and related HIV-conditions and medical treatment for TB, STDs,
1331 and hepatitis are important for HIV-infected persons.

1332 • **Partner Counseling and Referral Services**

1333 Persons with HIV-positive test results should receive or be referred to services to assist them in notifying
1334 their sex and/or injection drug equipment-sharing partners and/or spouses about their exposure to HIV and
1335 how to access counseling, testing, and referral services. See guidelines on partner counseling and referral
1336 services (33).

1337 • **Reproductive Health Services**

1338 Female clients who are pregnant or of childbearing age should receive or be referred to reproductive
1339 health services. HIV-infected pregnant women should receive referral to providers who can provide

1340 prevention counseling and education, initiate medical therapy to prevent perinatal transmission, and provide
1341 appropriate care pursuant to established treatment guidelines (30).

1342 • **Drug or Alcohol Prevention and Treatment**

1343 Clients who abuse drugs or alcohol should receive or be referred to substance abuse or alcohol prevention
1344 and treatment services.

1345 • **Prevention Case Management**

1346 Clients with multiple and complex needs that affect their ability to adopt and sustain behaviors to reduce
1347 their risk for transmission or acquisition of HIV should receive or be referred to prevention case
1348 management services, including ongoing prevention counseling (34).

1349 • **Mental Health Services**

1350 Clients who have mental illness, developmental disability, or difficulty coping with HIV diagnosis or HIV
1351 and HIV-related conditions should receive or be referred to appropriate mental health services.

1352 • **STD Screening and Care**

1353 Clients who are HIV-infected or at increased risk for HIV are at risk for other STDs and should receive
1354 or be referred for STD screening and treatment (146).

1355 • **Screening and Treatment for Viral Hepatitis**

1356 Clients who are HIV-infected or at increased risk for HIV are at increased risk for acquiring viral
1357 hepatitis, particularly hepatitis B and C. Such clients should receive or be referred for vaccination (for
1358 hepatitis B), testing for hepatitis B and C, and appropriate medical treatment.

1359 • **Other Services**

1360 Clients may have multiple needs that can be addressed through a variety of HIV prevention and other
1361 support services such as assistance with housing, food, employment, transportation, child care, domestic
1362 violence, and legal services. Addressing these needs can assist clients in accessing and accepting medical
1363 services and facilitate the adoption and maintenance of behaviors to reduce the risk for
1364 transmission/acquisition of HIV. Clients should receive referrals to such services as appropriate to
1365 identified needs.

1366 **5.6 Implementing and Managing Referral Services**

1367

1368 **Clients should be provided with assistance in accessing and completing referrals. Completion of**
1369 **referrals should be verified.**

1370 In the context of HIV prevention counseling and testing, the following should be considered key elements in the
1371 development and delivery of referral services (96).

1372 **5.6.1 Assessing Client Referral Needs**

1373 In consultation with the client, providers should identify factors that are likely to influence the client's ability to
1374 adopt or sustain behaviors to reduce risk for transmission or acquisition of HIV or that promote health and prevent
1375 disease progression. Assessment should include examination of the client's willingness and ability to accept and
1376 complete a referral. Service referrals that match the client's self-identified priority needs are more likely to be
1377 successfully completed than those not matching client priorities (147). Priority should be placed on ensuring that
1378 HIV-infected clients are assessed for referral needs related to clinical management of HIV infection, partner
1379 counseling and referral services, and prevention services aimed at reducing the risk for further transmission of
1380 HIV.

1381 When a provider does not have the capacity to make appropriate referrals or when client needs are especially
1382 complex, referral to a case management system should be made.

1383 **5.6.2 Planning the Referral**

1384 Referral services should be responsive to the clients' needs and priorities and should be provided in a manner that
1385 is appropriate given the client's culture, language, gender, and age. In consultation with the client, providers should
1386 assess what factors, if any, may make it difficult for the client to complete the referral (e.g., lack of transportation
1387 or child care, client work schedule, cost) and address them. Research suggests that accessibility and convenience
1388 of services predict whether a referral will be completed (147).

1389 **5.6.3 Facilitating Client Access to Referral Services**

1390 Clients should be provided with information necessary to enable them to successfully access the referral service
1391 (e.g., contact name, eligibility requirements, location, hours of operation, telephone number). For some clients,
1392 however, this may not be sufficient. Research suggests that providing assistance (e.g., setting an appointment,
1393 addressing transportation needs) facilitates completion of referrals (62). Where anonymous testing is an option and
1394 the client chooses anonymous testing, consent will need to be obtained from the client before sharing identifying
1395 information necessary to facilitate the referral.

1396 Outreach workers and peer counselor/educators can serve as an important and effective resource to help clients
1397 identify needs and plan successful referrals (148). Multiple contacts with outreach workers predict completed
1398 referrals (147).

1399 **5.6.4 Documenting Referral and Follow-Up**

1400 Providers should assess and document whether the client accessed the referral services. If the client did not, the
1401 provider should determine why not; and if the client did, the provider should determine the client's degree of
1402 satisfaction. If the services were unsatisfactory, the provider should offer additional or different referrals. Expert
1403 opinion suggests that documentation of referrals made, the status of those referrals, and client satisfaction with
1404 referrals will assist providers in better meeting the needs of clients. Information obtained through follow-up of
1405 referrals can identify barriers to completing the referral, responsiveness of referral services in addressing client
1406 needs, and gaps in the referral system.

1407 **5.7 Ensuring High-Quality Referral Services**

1408 **Providers of referral services should know and understand the service needs of their clients, be aware**
1409 **of available community resources, and be able to provide services in a culturally, linguistically, gender-,**
1410 **and age-appropriate manner.**

1411 **5.7.1 Education and Support of Staff**

1412 **Staff providing referral services must possess appropriate knowledge of client needs, the skills and**
1413 **resources to address them, and authority to assist the client in procuring services. Providers should**
1414 **develop protocols to ensure that staff receive adequate training and continuing education.**

1415 **Training and Education.** Providers should ensure that staff receive adequate training and continuing education to
1416 develop and maintain knowledge, skills, abilities (including competence in providing culturally, linguistically, gender-,
1417 and age-appropriate services) essential to implement and manage referrals. Training and education should address
1418 what resources are available and methods for managing referrals. Training and education should also promote
1419 understanding of factors likely to influence the client's ability and willingness to use a referral service (e.g.,
1420 readiness to accept the service, competing priorities, financial resources). Research suggests that a provider's
1421 ability to correctly evaluate a client's readiness to adopt risk-reducing behaviors predicts completed referrals (147).
1422 Research suggests that cross-training can facilitate fuller knowledge and understanding among providers of

1423 available community resources and suggest gaps in the service array (62).

1424 **Authority.** Staff providing referrals must have the authority necessary to accomplish a referral. This may relate to
1425 the authority of one provider to refer to another (e.g., through memoranda of agreement) or to obtain client consent
1426 for release of medical or other personal information. In providing referral services, the provider should maintain the
1427 confidentiality of client records pursuant to local, state, and federal regulations and established agency policy.

1428 **Advocacy.** Staff negotiating referrals must possess the knowledge and skills to advocate for the client. Such
1429 advocacy can help clients obtain services by mediating barriers to access to services and promoting an
1430 environment in which providers are better informed about the needs and priorities of their clients.

1431 **5.7.2 Provider Coordination and Collaboration**

1432 **Providers should develop and maintain strong working relationships with other providers and agencies**
1433 **that may be able to provide needed services. Coordination and collaboration should be formally**
1434 **documented.**

1435 Providers who offer HIV prevention counseling and testing services but not a full range of medical and
1436 psychosocial support services should develop direct, clearly delineated arrangements with other providers who can
1437 offer needed services. Such coordination and collaboration promotes a shared understanding of the specific
1438 medical and psychosocial needs of target populations, current resources available to address these needs, and gaps
1439 in resources.

1440 Memoranda of agreement are useful in outlining provider/agency relationships and delineating roles and
1441 responsibilities of collaborating providers in managing referrals. Where confidential client information is shared
1442 between coordinating providers, such formal agreements are essential. Interagency agreements should be
1443 reviewed periodically and modified as appropriate.

1444 **5.7.3 Referral Resources**

1445 **Providers of HIV prevention counseling and testing services should maintain accurate and current**
1446 **information regarding referral services.**

1447 Knowledge of available support services is essential to facilitating successful referrals. Some services
1448 may not be available locally. A resource guide should be developed and maintained to assist staff in making
1449 appropriate referrals (Box 7).

1450 Information about community resources can be obtained from local health planning councils, consortia, and
1451 community planning groups. Local, state, and national HIV/AIDS information hotlines and/or Web pages
1452 (such as NPIN's), other community-based health and human service providers, and state and local public
1453 health departments may also serve as sources for such information.

1454 **Box 7. Contents of Referral Resource Guide**

1455 For each resource, the referral resource guide should specify

- 1456 • Name of the provider or agency
- 1457 • Range of services provided
- 1458 C Target population(s)
- 1459 C Service area(s)
- 1460 • Contact names and telephone and fax numbers, street addresses, e-mail addresses
- 1461 C Hours of operation
- 1462 C Location
- 1463 C Cultural, linguistic, gender, and age competence
- 1464 C Cost for services
- 1465 C Eligibility
- 1466 C Application materials
- 1467 C Admission policies and procedures
- 1468 C Directions, transportation information, and accessibility to public transportation
- 1469 C Client satisfaction with services

1420 **6.0 HIV Counseling, Testing, and Referral in Nontraditional Settings**

1421 **6.1 Background**

1422 **Counseling, testing, and referral services should be provided in community-based and outreach**
1423 **settings, as well as clinical settings.**

1424 Providers of HIV counseling, testing and referral services are strongly encouraged to expand provision of
1425 services into nontraditional settings such as community-based organizations and outreach settings. Doing
1426 so may facilitate use of these services by persons at increased risk for HIV, according to data from
1427 publicly supported counseling, testing, and referral programs. When HIV counseling, testing, and referral
1428 services are not readily available, accessible, or acceptable, persons at increased risk for HIV may not
1429 take advantage of them.

1430 Expansion of counseling, testing, and referral services into nontraditional settings can be accomplished
1431 through

- 1432 • Partnership with community-based health and human service providers
- 1433 • Use of new FDA-approved HIV test technologies that offer less invasive sample collection,
1434 portability, low complexity sample collection and processing, and reduced bio-hazard

1435 **6.2 Ensuring High-Quality Services in Nontraditional Settings**

1436 **To ensure high-quality services responsive to client needs, agencies should develop and**
1437 **implement written quality assurance protocols and procedures specific to provision of services**
1438 **in nontraditional settings.**

1439 Expansion of counseling, testing, and referral into nontraditional settings presents challenges related to
1440 providing high-quality services. For example, issues related to client privacy and confidentiality, informed
1441 consent, counseling, testing, provision of test results, referral, record keeping, and staff safety must be
1442 considered during development of protocols and procedures regarding provision of services in
1443 nontraditional settings.

1444 **Privacy and Confidentiality.** Ensuring clients' privacy and confidentiality during the counseling, testing,
1445 and referral process is essential but may present unique challenges in some nontraditional settings.
1446 Confidentiality can more easily be breached in settings where clients and providers can be seen or heard
1447 by others. Suggested strategies for maintaining privacy and confidentiality in nontraditional settings include

- 1448 • Use a separated area in a mobile van
- 1449 • Use rooms with locking doors
- 1450 • Mark a specific room with a "do not disturb" or "occupied" sign
- 1451 • Designate an area of a facility that provides physical privacy
- 1452 • In parks and similar locations, seek areas with as much privacy as possible
- 1453 • Provide counseling and testing services in the client's home or other secure setting
- 1454 • Have client return to provider/agency to receive test results and posttest counseling and referral

1455
1456 **Informed Consent.** Staff providing counseling, testing, and referral services should be sensitive to issues
1457 that may interfere with obtaining true informed consent (see 2.4). Such issues include use of
1458 alcohol/drugs, mental illness, and peer pressure in venues where people congregate or socialize.
1459 Suggested strategies for obtaining informed consent during provision of services in nontraditional settings
1460 include

- 1461 • Schedule an appointment to test at a later date/time
- 1462 • Follow up at a later time with the client if contact information is available
- 1463 • Read informed consent to client
- 1464 • Use verbal prompts to ensure that the client understands consent

1465 **Counseling.** Staff working in community-based and other nontraditional settings should be familiar with
1466 risk screening strategies to determine whether HIV prevention counseling should be offered (see 2.5.6).
1467 Staff should be trained in HIV prevention counseling or other approaches aimed at personal HIV risk
1468 reduction. When appropriate (e.g., among injecting drug users), information about other STDs and
1469 bloodborne diseases should be incorporated into the counseling sessions (35,149) (see 3.4.6).

1470 **Testing.** The decision to offer HIV testing in nontraditional settings should be based on several factors,
1471 including availability of resources and feasibility of providing test results and follow-up. In some cases,
1472 referral to other providers is appropriate. The selection of a specific HIV test technology should be based
1473 on logistical issues such as field conditions related to collection, transport, and storage of specimens;
1474 worker safety; and the likelihood that clients will receive HIV test results. Providers must fully understand
1475 the extent to which "field conditions" may affect specimens (e.g., extreme temperatures, time lapse from
1476 collection to processing). Test specimens should be collected, stored, and transported pursuant to

1477 manufacturer instructions.

1478 **Provision of Test Results.** Clear protocols for provision of test results and prevention counseling should
1479 be developed. The following strategies may be useful in ensuring the provision of results in nontraditional
1480 settings:

- 1481 • Provide a telephone number that clients can call to receive test results
- 1482 • Make an appointment with the client, at the time of testing, for receiving results
- 1483 • Make incentives available (e.g., food certificates, hygiene kits, food)
- 1484 • Return to a site on a regularly scheduled basis
- 1485 • Provide reminders when contact information is available

1486 **Referral.** Staff working in community-based and other nontraditional settings should receive training in
1487 the implementation and management of referrals. Providers should establish appropriate collaborative
1488 relationships to facilitate referrals. Arranging for partner counseling and referral services staff and/or
1489 case managers to be available to clients at the time test results are provided may facilitate referral.

1490 **Record Keeping.** Maintaining the confidentiality of client records is critical. Providers should develop
1491 written protocols for record keeping that address transport of client records to and from outreach venues.
1492 Strategies to maintain confidentiality of client records in nontraditional settings include

- 1493 • Return all client records to the office immediately after the counseling, testing, and referral session
- 1494 • Use codes or unique identifiers rather than client names
- 1495 • Store all records in a secured area (e.g., locked file drawers)
- 1496 • Provide counseling and testing on an anonymous basis only
- 1497 • When providing test results, verify identity of client (e.g. match client signature with that provided for
1498 informed consent; check identification card)
- 1499 • Store paperwork in a lockbox while in outreach settings
- 1500 • Password protect and encrypt electronically stored client records

1501 Where allowed by state/local statute, clients may elect to be tested for HIV anonymously. Procedures to
1502 ensure client's anonymity with respect to HIV testing (i.e., no indication of testing in a client's record and
1503 no recording of personal identifying information on laboratory requests) should be developed. Even when
1504 staff who provide counseling, testing, and referral services know the client (including names and locating
1505 information) from other activities, the client's right to be tested anonymously should be protected.

1506

1507 **Staff Safety.** Providing services in outreach settings such as bars and parks may compromise staff safety,
1508 which must be considered in development of outreach protocols. Appropriate training and precautions,
1509 such as working in teams, should be developed in planning for services in nontraditional settings.

1510 **7.0 Quality Assurance and Evaluation of HIV Counseling, Testing, and Referral Services**

1511 In these guidelines, the role of quality assurance and evaluation has been expanded and strengthened.
1512 Quality assurance activities are needed to ensure provision of high-quality services. Evaluation focuses on
1513 ways to improve the overall benefit of prevention services.

1514 **7.1 Quality Assurance**

1515 **Written quality assurance protocols should be developed and routinely followed by providers of**
1516 **HIV counseling, testing, and referral services.**

1517 Written quality assurance protocols should be developed and made available to all staff providing
1518 counseling, testing, and referral services. General components of quality assurance activities follow, and
1519 issues specific to ensuring high-quality counseling, testing, and referral services are included in 3.4.8, 4.10,
1520 and 5.7, respectively. All staff should receive training and orientation about quality assurance.

1521 Quality assurance activities should address the following:

- 1522 • Accessibility of services (e.g., hours of operation, location, availability of supplies and materials such
1523 as brochures, posters, test kits, safe injection materials, condoms, lubricant)
- 1524 • Compliance with written protocols for provision of service to an individual client (e.g., appropriate
1525 counseling protocols, timely return of HIV test results to clients, referral for services responsive to
1526 client's priority needs)
- 1527 • Cultural, linguistic, gender, and age appropriateness of services and materials
- 1528 • Staff performance/proficiency (e.g., competence, skills, credentials, and training)
- 1529 • Supervision of staff, including routine timely feedback to staff
- 1530 • Compliance with program guidelines and performance standards
- 1531 • Appropriateness of services to client needs, measured with client satisfaction tools (e.g., surveys or
1532 suggestion boxes)
- 1533 • Record keeping procedures, including confidentiality and security
- 1534 • Community resources (availability and collaborative arrangements)
- 1535 • Collection, handling, and storage of specimens
- 1536 • Assurance of adequate funding and institutional support for counseling, testing, and referral services.

1537 **7.2 Evaluation**

1538

1539 **Counseling, testing, and referral services should be regularly evaluated.**

1540 Evaluation of public or private counseling, testing, and referral services should be viewed as an essential
1541 activity and a continual process to improve services to clients and provide accountability to stakeholders
1542 (150,151). Evaluation should be an interactive process involving individuals and organizations affected by
1543 the service (150). In public health settings, the goals of the community as described by community health
1544 planning processes and other relevant local planning processes could be incorporated into the evaluation
1545 process.

1546 Providers need to identify the key relevant, programmatic goals and objectives that reflect provision of
1547 services to the program, community, and individual client and determine what data are needed to evaluate
1548 those goals and objectives. Information obtained from the evaluation process should be used to plan and
1549 prioritize the provision of counseling, testing, and referral services within a setting. For example,
1550 information from the HIV Counseling and Testing System (CTS) (42) or other locally available sources
1551 could be used during the local community planning process (e.g., the HIV prevention community planning
1552 process) to assist in developing or revising an HIV/AIDS prevention plan and/or describing the target
1553 population in need of services. Since resources for evaluation may be limited, comprehensive evaluations
1554 (including outcome evaluation and impact evaluation, for example) are often not possible. However, even
1555 with limited resources, providers can conduct meaningful evaluations by focusing on relevant local
1556 outcomes (75).

1557 **7.2.1 Data**

1558 **Data collected should have a clear, anticipated use and should not be the focus of or interfere**
1559 **with the provision of counseling, testing, or referral services.**

1560

1561 Data should be used to evaluate the extent to which the goals of counseling, testing, and referral and
1562 locally defined service outcomes (e.g., targeted return rates, knowledge of HIV infection status,
1563 proportion of successful referrals) are met.

1564 While high-quality data are essential for evaluation of services, the primary purpose of each visit should

1565 be to provide the best possible service to the client. Data should be recorded outside the time reserved for
1566 counseling, testing, or referral discussions between the provider and the client. Examples of approaches to
1567 data collection include having the client complete a questionnaire or intake information form on admission,
1568 having a provider complete these forms immediately after a meeting with a client has ended, or combining
1569 these two approaches.

1570 Data collection methods should be compatible with the evaluation needs of the counseling, testing, and
1571 referral service setting. Data should be collected by using a standard collection instrument throughout the
1572 program. Simple data collection instruments (e.g., intake forms, medical record reviews) should be
1573 developed so that data can be collected unobtrusively as part of the provision of services.

1574 Publicly funded counseling, testing, and referral sites currently collect data on client demographic
1575 characteristics, risk behavior/exposure category, test acceptance, and type of site where service is
1576 provided. Most sites record the date of visit, anonymous or confidential test status, previous test result,
1577 current test result, and return for current test result from each client encounter. Additional data may be
1578 useful for evaluation of services, such as date of previous test, type of current test (e.g., standard, rapid,
1579 oral), risk-reduction plan summary, information relevant to any referrals made (e.g., provider and service
1580 description, information and materials provided, whether an appointment was made), whether the referral
1581 was received, type of service provided, dates when services were provided, and other relevant
1582 information (e.g., follow-up required, additional service needs).

1583 7.2.2 Confidentiality

1584 **Any data collected or recorded must be collected or recorded in a manner that ensures the**
1585 **confidentiality of the client.**

1586 Clear procedures and protocol manuals must be developed and utilized to ensure that any data gathered
1587 and maintained will not compromise client confidentiality.

1588 7.2.3 Ensuring High-Quality Evaluation

- 1589 • **Monitor.** The system used to collect the information must be monitored periodically to ensure high
1590 data quality, which depends on the cooperative efforts of all persons providing counseling, testing, and
1591 referral services. Periodically, data collection systems should check records at each level of the data
1592 collection process to ensure that information is recorded consistently and completely.

- 1593 • **Train.** Adequate training in the use of data collection instruments should be provided to all staff
1594 members to ensure that the evaluation process is not interfering with the provision of high-quality
1595 counseling, testing, and referral services.

- 1596 • **Expedite.** The information assembled during the evaluation process should be analyzed and reported
1597 in a timely fashion to individuals and organizations affected by the service.

- 1598 • **Apply.** Whenever feasible, the information and feedback gained during the evaluation process should
1599 be used to improve the services offered by the site to the client.

1600

Glossary

1601 **AIDS:** Acquired immunodeficiency syndrome. AIDS can affect the immune and central nervous systems
1602 and can result in neurological problems, infections, or cancers. It is caused by human immunodeficiency
1603 virus (HIV).

1604 **anal sex:** A type of sexual intercourse in which a man inserts his penis in his partner's anus. Anal sex
1605 can be insertive or receptive.

1606 **anonymous:** Without any personally identifying information. With regard to HIV testing, it means that the
1607 persons ordering and performing the test do not maintain a record of the name or other personal
1608 identifiers of the person whose specimen they are testing.

1609 **antiretroviral therapy:** Treatment with drugs designed to prevent HIV from replicating in HIV-infected
1610 persons. Highly active antiretroviral therapy (HAART) is an antiretroviral regimen that includes multiple
1611 classifications of antiretroviral drugs.

1612 **client-centered HIV prevention counseling:** An interactive risk-reduction counseling model usually
1613 conducted with HIV testing, in which the counselor helps the client identify, acknowledge personal HIV
1614 risk behaviors, and commit to a single, achievable behavior change step that could reduce the client's HIV
1615 risk.

1616 **confidentiality:** Pertains to the disclosure of personal information in a relationship of trust and with the
1617 expectation that it will not be divulged to others in ways that are inconsistent with the original disclosure.
1618 Confidentiality must be maintained for persons who are offered or receive HIV counseling, testing, and
1619 referral services.

1620 **confidential HIV test:** An HIV test for which a record of the test and the test results are recorded in
1621 the client's chart.

1622 **confirmatory test:** A highly specific test designed to confirm the results of an earlier (screening) test.
1623 For HIV testing, a Western blot or, less commonly, an immunofluorescence assay (IFA) is used as a
1624 confirmatory test.

1625 **EIA:** Enzyme immunoassay. Sometimes referred to as ELISA (see below). A commonly used screening
1626 test to detect antibodies to HIV.

1627 **ELISA:** Enzyme-linked immunosorbent assay. A type of EIA (see above). A commonly used screening
1628 test to detect antibodies to HIV.

1629 **evaluation:** A process for determining how well health systems, either public or private, deliver or
1630 improve services and for demonstrating the results of resource investments.

1631 **false negative:** A negative test result for a person who is actually infected.

1632 **false positive:** A positive test result for a person who is actually not infected.

1633 **freestanding HIV test site:** a publicly funded HIV counseling, testing, and referral program. Sometimes
1634 referred to as “alternate test site” or “anonymous test site.”

1635 **HIV:** Human immunodeficiency virus, the virus that causes AIDS.

1636 **HIV test:** More correctly referred to as an HIV antibody test, the HIV test is a laboratory procedure that
1637 detects antibodies to HIV, rather than the virus itself.

1638 **HIV prevention counseling:** An interactive process between client and counselor aimed at reducing
1639 risky sex and needle-sharing behaviors related to HIV acquisition (for HIV-uninfected clients) or
1640 transmission (for HIV-infected clients). See also client-centered HIV prevention counseling.

1641 **home sample collection test:** A test that a consumer purchases and uses to collect blood (or other
1642 bodily fluid) and then send it out for testing. Counseling and test results are typically provided by telephone
1643 using user-generated codes to ensure confidentiality and anonymity.

1644 **incidence:** In epidemiology, the number of new cases of infection or disease that occur in a defined
1645 population within a specified time period (i.e., the rate of incidence).

1646 **inconclusive test result:** Test results are inconclusive when nonspecific or insufficient antibody is
1647 present.

1648 **indeterminate test result:** A possible result of a Western blot, which may represent a recent HIV
1649 infection or a false-positive.

1650 **oral fluid test:** A test using oral mucosal transudate, a serous fluid. To differentiate this fluid from saliva,
1651 an absorbent material is left in the mouth for several minutes. In an HIV-infected person, the oral mucosal
1652 transudate is likely to contain HIV antibodies.

1653 **oral sex:** A type of sexual intercourse in which the partner’s genitals are stimulated by mouth and
1654 tongue.

1655 **partner counseling and referral services (PCRS):** A prevention activity that aims to provide services
1656 to HIV-infected persons and their sex and needle-sharing partners so they can reduce their risk for
1657 infection or, if already infected, can prevent transmission to others; and to help partners gain earlier
1658 access to individualized counseling, HIV testing, medical evaluation, treatment, and other prevention
1659 services.

1660 **perinatal HIV transmission:** Transmission of HIV from the mother to the fetus or infant during
1661 pregnancy, delivery, or breastfeeding.

1662 **positive test:** For HIV, a sample of serum that is reactive on an initial ELISA test, repeatedly reactive
1663 on a second ELISA run on the same specimen, and confirmed positive on Western blot or other
1664 supplemental test indicates that the client is infected.

1665 **prevalence:** The percentage of persons in a given population with a disease or condition at a given point
1666 in time.

1667 **prevention case management (PCM):** A client-centered HIV prevention activity that promotes
1668 adoption of HIV risk-reduction behaviors by clients with multiple, complex problems and risk-reduction
1669 needs. PCM is a hybrid of HIV prevention counseling and traditional case management that provides
1670 intensive, on-going, and individualized prevention counseling, support, and referral to other needed
1671 services.

1672 **prevention counseling:** See HIV prevention counseling.

1673 **quality assurance:** An ongoing process for ensuring that the counseling, testing, and referral program
1674 effectively delivers a consistently high level of service to the clients.

1675 **rapid HIV test:** A test to detect antibodies to HIV that can be collected and processed within a short
1676 interval of time (e.g., approximately 10-30 minutes).

1677 **referral:** The process through which a client is connected with services to address prevention needs
1678 (medical, prevention, and psychosocial support).

1679 **risk assessment:** Risk assessment is that portion of a client-centered HIV prevention counseling session
1680 in which the client is encouraged to identify and acknowledge his or her personal risk for acquiring or
1681 transmitting HIV.

1682 **risk screening:** An evaluation of HIV risk factors, both behavioral and clinical, used for decisions about
1683 who should be offered HIV counseling and testing. Risk screening is different from risk assessment.

1684 **screening test** (e.g., enzyme immunoassay [EIA] or enzyme-linked immunosorbent assay [ELISA]): An
1685 initial test, usually designed to be sensitive, to identify all persons with a given condition or infection.

1686 **sensitivity:** The probability that a test will be positive when infection or condition is present.

1687 **seroconversion:** Initial development of detectable antibodies specific to a particular antigen; the change
1688 of a serologic test result from negative to positive as a result of antibodies induced by the introduction
1689 antigens or microorganisms into the host.

1690 **specificity:** The probability that a test will be negative when the infection or condition is not present.

1691 **vaginal sex:** A type of sexual intercourse in which the man's penis enters the woman's vagina.

1692 **Western blot:** A laboratory test that detects specific antibodies to components of a virus. Chiefly used to
1693 confirm HIV antibodies in specimens found repeatedly reactive using ELISA.

References

1. Centers for Disease Control and Prevention. Current Trends: Additional Recommendations to Reduce Sexual and Drug Abuse-Related Transmission of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus. *Morbidity and Mortality Weekly Report* 1986;35(10):152-5.
2. Centers for Disease Control and Prevention. Perspectives in Disease Prevention and Health Promotion: Public Health Service Guidelines for Counseling and Antibody Testing to Prevent HIV Infection and AIDS. *Morbidity and Mortality Weekly Report: Recommendations and Reports* 1987;36(31):509-15.
3. Centers for Disease Control and Prevention. Technical Guidance on HIV Counseling. *Morbidity and Mortality Weekly Report: Recommendations and Reports* 1993;42(RR-2):5-9.
4. Centers for Disease Control and Prevention. HIV Counseling, Testing and Referral Standards and Guidelines. Atlanta. Centers for Disease Control and Prevention. 1994.
5. Kamb ML, Fishbein M, Douglas J, Rhodes F, Rogers J, Bolan G, Zenilman J, Hoxworth T, Malotte K, Iatesta M, et al. Efficacy of Risk-Reduction Counseling to Prevent Human Immunodeficiency Virus and Sexually Transmitted Diseases: A Randomized Controlled Trial. *Journal of the American Medical Association* 1998;280(13):1161-7.
6. Roffman R, Kalichman S, Kelly J, Winett R, Solomon L, Sikkema K, Norman A, Desiderato L, Perry M, Lemke A et al. HIV antibody testing of gay men in smaller US cities. *AIDS Care* 1995;7(4):405-13.
7. The National Institutes of Mental Health (NIMH) Multisite HIV Prevention Trial Group. The NIMH Multisite HIV Prevention Trial: Reducing HIV Sexual Risk Behavior. *Science* 1998;280(5371):1889-94.
8. Boyer C, Barrett D, Peterman T, Bolan G. Sexually transmitted disease (STD) and HIV risk in heterosexual adults attending a public STD clinic: evaluation of a randomized controlled behavioral risk-reduction intervention trial. *AIDS* 1997;11(3):359-67.
9. St.Lawrence J, Brasfield TL, Jefferson KW, Alleyne E, O'Bannon RE, and Shirley A. Cognitive-Behavioral Intervention to Reduce African American Adolescents' Risk for HIV Infection. *Journal of Consulting and Clinical Psychology* 1995;63(2):221-37.
10. DiClemente R, Wingood G. A Randomized Controlled Trial of an HIV Sexual Risk-Reduction Intervention for Young African-American Women. *Journal of the American Medical Association* 1995;274(16):1271-6.
11. Kelly JA, Murphy DA, Washington CD, Wilson TS, Koob JJ, Davis DR, Ledezma G, and Davantes B. The Effects of HIV/AIDS Intervention Groups for High-Risk Women in Urban Clinics. *American Journal of Public Health* 1994;84(12):1918-22.

12. Tudiver F, Myers T, Kurtz R, Orr K, Rowe C, Bullock S, Jackson E. The Talking Sex Project. Evaluation and the Health Professions 1992;15(4):26-42.
13. Wenger N, Linn L, Epstein M, Shapiro M. Reduction of High-Risk Sexual Behavior among Heterosexuals Undergoing HIV Antibody Testing: A Randomized Clinical Trial. American Journal of Public Health 1991;81(12):1580-5.
14. Orr D, Langefeld C, Katz B, and Caine V. Behavioral intervention to increase condom use among high-risk female adolescents. The Journal of Pediatrics 1996;128(2):288-95.
15. Hobfoll SE, Jackson AP, Lavin J, Britton PJ, and Shepherd JB. Reducing Inner-City Women's AIDS Risk Activities: A Study of Single, Pregnant Women. Health Psychology 1994;13(5):397-403.
16. Kelly JA, St.Lawrence J, Hood H, and Brasfield T. Behavioral Intervention to Reduce AIDS Risk Activities. Journal of Consulting and Clinical Psychology 1989;57(1):60-7.
17. Kelly JA, St.Lawrence JS, Diaz YE, Stevenson LY, Hauth AC, Brasfield TL, Kalichman SC, Smith JE, Andrew ME. HIV Risk Behavior Reduction following Intervention with Key Opinion Leaders of Population: An Experimental Analysis. American Journal of Public Health 1991;81(2):168-71.
18. Valdiserri RO, Lyter DW, Leviton LC, Callahan CM, Kingsley LA, and Rinaldo CR. AIDS prevention in homosexual and bisexual men: results of a randomized trial evaluating two risk reduction interventions. AIDS 1989;3(1):21-6.
19. Jemmott JB3, Jemmott LS, Fong GT. Reductions in HIV Risk-Associated Sexual Behaviors among Black Male Adolescents: Effects of an AIDS Prevention Intervention. American Journal of Public Health 1992;82(3):372-7.
20. Shain RN, Piper JM, Newton ER, Perdue ST, Ramos R, Champion JD, and Guerra FA. A Randomized, Controlled Trial of a Behavioral Intervention to Prevent Sexually Transmitted Disease Among Minority Women. The New England Journal of Medicine 1999;340(2):93-100.
21. O'Donnell C, O'Donnell L, Sandoval A, Duran R, Labes K. Reductions in STD Infections Subsequent to an STD Clinic Visit: Using Video-Based Patient Education to Supplement Provider Interactions. Sexually Transmitted Diseases 1998;25(3):161-7.
22. Cohen D, MacKinnon D, Dent C, Mason H, and Sullivan E. Group Counseling at STD Clinics to Promote Use of Condoms. Public Health Reports 1992;107(6):727-31.
23. Cohen D, Dent C, and MacKinnon D. Condom Skills Education and Sexually Transmitted Disease Reinfection. The Journal of Sex Research 1991;28(1):139-44.
24. Rietmeijer CA, Kane MS, and Simons PZ. Increasing the use of bleach and condoms among injecting drug users in Denver: outcomes of a targeted, community-level HIV prevention program. AIDS 1996;10:291-8.
25. Rhodes F, Malotte CK. HIV risk interventions for active drug users. In: S.Oskamp, S.Thompson, editors. Understanding HIV risk behavior: safer sex and drug use. Thousand Oaks: Sage

Publications 1996. p. 297-36.

26. Gibson D. Effectiveness of brief counseling in reducing HIV risk behavior in injecting drug users: Final results of randomized trials of counseling with and without HIV testing. *AIDS and Behavior* 1999;3(1):3-12.
27. Palella F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G, Aschman D, and Holmberg S. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. *The New England Journal of Medicine* 1998;338(13):853-60.
28. Centers for Disease Control and Prevention. 1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. *Morbidity and Mortality Weekly Report* 1999;48(RR-10):1-59.
29. Connor E, Sperling R, Gelber R, Kiselev P, Scott G, O'Sullivan M, VanDyke R, Bey M, Shearer W, Jacobson R et al. Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 With Zidovudine Treatment. *The New England Journal of Medicine* 1994;331(18):1173-80.
30. Centers for Disease Control and Prevention. Revised HIV Counseling and Testing Guidelines for Pregnant Women. In preparation, 2000.
31. Kassler W. Advances in HIV Testing Technology and Their Potential Impact on Prevention. *AIDS Education and Prevention* 1997;9(Supplement B):27-40.
32. Spielberg B, Goldbaum G, Branson B, et al. Acceptance of alternate HIV counseling and testing strategies. 1999 National HIV Prevention Conference, Atlanta, Georgia, 1999.
33. Centers for Disease Control and Prevention. HIV Partner Counseling and Referral Services - Guidance. U.S. Department of Health and Human Services - Public Health Services. 1998.
34. Centers for Disease Control and Prevention. HIV Prevention Case Management - Guidance. Atlanta, Georgia. U.S. Department of Health and Human Services - Public Health Services. 1997.
35. Centers for Disease Control and Prevention. 1998 Guidelines for Treatment of Sexually Transmitted Diseases. *Morbidity and Mortality Weekly Report: Recommendations and Reports* 1998;47(RR-1):1-117.
36. Centers for Disease Control and Prevention. 1997 USPHS / IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. *Morbidity and Mortality Weekly Report: Recommendations and Reports* 1997;46(RR-12):1-46.
37. United States Preventive Services Task Force. DiGiuseppi, C., Atkins, D., and Woolf, S., editors. *Guide to Clinical Preventive Services*. Baltimore, MD: Williams & Wilkins. 1996.
38. Centers for Disease Control and Prevention. *CDC Guidelines: Improving the Quality*. Atlanta (GA): Centers for Disease Control and Prevention; 1996.
39. Centers for Disease Control and Prevention. *HIV/AIDS Surveillance Report (U.S. HIV and AIDS cases reported through December 1999)*. Atlanta. 2000.

40. Karon J, Rosenberg P, McQuillan G, Khare M, Gwinn M, and Petersen L. Prevalence of HIV Infection in the U.S., 1984-1992. *Journal of the American Medical Association* 1996;276(2):126-31.
41. Centers for Disease Control and Prevention. CDC Guidelines for National Human Immunodeficiency Virus Case Surveillance, Including Monitoring for Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. *Morbidity and Mortality Weekly Report* 1999;48(RR-13):1-31.
42. Centers for Disease Control and Prevention. HIV Counseling and Testing in Publicly Funded Sites: 1996 Annual Report. Atlanta: Centers for Disease Control and Prevention 1996;1-26.
43. Branson BM. Home Sample Collection Tests for HIV Infection. *Journal of the American Medical Association* 1998;280(19):1699-701.
44. Bindman AB, Osmond D, Hecht FM, Lehman JS, Vranizan K, Keane D, and Reingold A. Multistate Evaluation of Anonymous HIV Testing and Access to Medical Care. *Journal of the American Medical Association* 1998;280(16):1416-20.
45. Chen Z, Branson B, Ballenger A, and Peterman T. Risk Assessment to improve targeting of HIV counseling and testing services of STD clinic patients. *Sexually Transmitted Diseases* 1998;25(10):539-43.
46. Quinn T, Glasser D, Cannon R, Matuszak D, Dunning R, Kline R, Campbell C, Israel E, Fauci A, and Hook E. Human Immunodeficiency Virus Infection Among Patients Attending Clinics for Sexually Transmitted Diseases. *The New England Journal of Medicine* 1988;318(4):197-203.
47. Erickson B, Wasserheit J, Rompalo A, Brathwaite W, Glasser D, and Hook E. Routine Voluntary HIV Screening in STD Clinic Clients: Characterization of Infected Clients. *Sexually Transmitted Diseases* 1990;17(4):194-9.
48. Groseclose S, Erickson B, Quinn T, Glasser D, Campbell C, and Hook E. Characteristics of Patients Accepting and Refusing Routine Voluntary HIV Antibody Testing in Public Sexually Transmitted Disease Clinics. *Sexually Transmitted Diseases* 1994;21(1):31-5.
49. Kassler W, Zenilman J, Erickson B, Fox R, Peterman T, and Hook E. Seroconversion in patients attending sexually transmitted disease clinics. *AIDS* 1994;8(3):351-5.
50. Asch S, London A, Barnes P, Gelberg L. Testing for Human Immunodeficiency Virus Infection among Tuberculosis Patients in Los Angeles. *American Journal of Respiratory Critical Care Medicine* 1997;155(1):378-81.
51. Pitchenik A, Burr J, Suarez M, Fertel D, Gonzalez G, Moas C. Human T-Cell Lymphotropic Virus-III (HTLV-III) Seropositivity and Related Disease Among 71 Consecutive Patients in Whom Tuberculosis was Diagnosed. *American Review of Respiratory Disease* 1987;135(4):875-9.
52. Shafer R, Chirgwin K, Glatt A, Dahdouh M, Landesman S, Suster B. HIV prevalence, immunosuppression, and drug resistance in patients with tuberculosis in an area endemic for AIDS.

AIDS 1991;5(4):399-405.

53. Theuer C, Hopewell P, Elias D, Schechter G, Rutherford G, and Chaisson R. Human Immunodeficiency Virus Infection in Tuberculosis Patients. *The Journal of Infectious Diseases* 1990;162(1):8-12.
54. Peterman T, Todd K, Mupanduki I. Opportunities for Targeted Publicly Funded Human Immunodeficiency Virus Counseling and Testing. *Journal of Acquired Immunodeficiency Syndromes* 1996;12(1):69-74.
55. Centers for Disease Control and Prevention. Public Health Service Guidelines for the Management of Health-Care Worker Exposures to HIV and Recommendations for Postexposure Prophylaxis. *Morbidity and Mortality Weekly Report: Recommendations and Reports* 1998;47(RR-7):1-33.
56. Centers for Disease Control and Prevention. Management of Possible Sexual, Injecting-Drug-Use, or Other Nonoccupational Exposure to HIV, Including Considerations Related to Anti-Retroviral Therapy. *Morbidity and Mortality Weekly Report: Recommendations and Reports* 1998;47(RR-17):1-14.
57. Janssen R, St.Louis M, Satten G, Critchley S, Petersen L, Stafford R, Ward J, Hanson D, Olivo N, Schable C, et al. HIV Infection Among Patients in U.S. Acute Care Hospitals: Strategies for the Counseling and Testing of Hospital Patients. *The New England Journal of Medicine* 1992;327(7):445-52.
58. Tao G, Irwin KL, Kassler WJ. Missed Opportunities to Assess STDs in US Adults during Routine Medical Checkups. *American Journal of Preventive Medicine* 2000;18:109-14.
59. Centers for Disease Control and Prevention. HIV prevention practices of primary care physicians -- United States. *Morbidity and Mortality Weekly Report* 1994;42(51):988-92.
60. Tiara D, Safran D, Seto T, Rogers W, and Tarlov A. The relationship between patient income and physician discussion of health risk behaviors. *Journal of the American Medical Association* 1997;278(17):1412-7.
61. Schwartz J, Lewis C, Clancy C, Kinosian M, Radany M, and Koplan J. Internists' practices in health promotion and disease prevention. *Annals of Internal Medicine* 1991;114(1):46-53.
62. Marx R, Hirozawa A, Chu P, Bolan G, and Katz M. Linking clients for HIV antibody counseling and testing to prevention services. *Journal of Community Health* 1999;24(3):201-14.
63. Doll L, O'Malley P, Pershing A, Darrow W, Hessol N, and Lifson A. High-Risk Sexual Behavior and Knowledge of HIV Antibody Status in the San Francisco City Clinic Cohort. *Health Psychology* 1990;9(3):253-65.
64. Cleary P, Van Devanter N, Rogers T, Singer E, Shipton-Levy R, Steilen M, Stuart A, Avorn J, and Pindyck J. Behavior Changes after Notification of HIV Infection. *American Journal of Public Health* 1991;81(12):1586-90.
65. Fox R, Odaka NJ, Brookmeyer R, and Polk BF. Effect of HIV Antibody Disclosure on

- Subsequent Sexual Activity in Homosexual Men. *AIDS* 1987;1(4):241-6.
66. van Griensven G, de Vroome E, Tielman RA, Goudsmit J, de Wolf F, van der Noordaa J, and Coutinho RA. Effect of Human Immunodeficiency Virus (HIV) Antibody Knowledge on High-Risk Sexual Behavior with Steady and Nonsteady Sexual Partners among Homosexual Men. *American Journal of Epidemiology* 1989;129(3):596-603.
67. Coates T, Morin S, and McCusick L. Behavioral consequences of AIDS antibody testing among gay men [letter]. *Journal of the American Medical Association* 1987;258(14):1889.
68. Kelly JA and St.Lawrence JS. The Prevention of AIDS: Roles for Behavioral Intervention. *Scandinavian Journal of Behaviour Therapy* 1987;16(1):5-19.
69. Cohen D, Dent C, MacKinnon D, and Hahn G. Condoms for Men, Not Women: Results of Brief Promotion Programs. *Sexually Transmitted Diseases* 1992;19(5):245-51.
70. Sikkema KJ and Bissett R. Concepts, Goals, and Techniques of Counseling: Review and Implications for HIV Counseling and Testing. *AIDS Education and Prevention* 1997;9(Supplement B):14-26.
71. Kelly JA and St.Lawrence JS. Behavioral Intervention and AIDS. *The Behavioral Therapist* 1986;9(6):121-5.
72. Kamb ML, Dillon BA, Fishbein M, Willis KL, and Project RESPECT Study Group. Quality Assurance of HIV Prevention Counseling in a Multi-Center Randomized Controlled Trial. *Public Health Reports* 1996;111(Supplement 1):99-107.
73. Jimerson AB, DeGroff A, Schechter C, Blake S, and Hanlong E. Why Have Some States Adopted HIV Prevention Counseling While Others Have Not?: Applying Diffusion Theory. Submitted for publication.
74. Holtgrave D, Valdiserri R, Gerber R, and Hinman A. Human Immunodeficiency Virus Counseling, Testing, Referral, and Partner Notification Services: A Cost-Benefit Analysis. *Archives of Internal Medicine* 1993;153(10):1225-30.
75. Holtgrave D, Reiser W, and DiFranceisco W. The Evaluation of HIV Counseling and Testing Services: Making the Most of Limited Resources. *AIDS Education and Prevention* 1997;9(Supplement B):105-18.
76. Kamb ML, Kessler W, Peterman T, Zenilman J, Bolan G, Rogers J, and Rhodes F. Cost of preventing HIV via counseling: results from a randomized trial (Project RESPECT). XII International Conference on AIDS; 1998; Geneva, Switzerland. Abstract no. 33263. p. 644.
77. Booth R, Kwiatkowski CF, and Stephens RC. Effectiveness of HIV/AIDS interventions on drug use and needle risk behaviors for out-of-treatment injection drug users. *Journal of Psychoactive Drugs* 1998;30 (3)269-78.
78. Castrucci B. Assessing CDC's Counseling, Testing, and Referral Standards and Guidelines:

How Closely Does Practice Conform to Existing Recommendations? Submitted for publication to Public Health Reports.

79. Kelly JA, Murphy DA, Sikkema KJ, and Kalichman SC. Psychological Interventions to Prevent HIV Infection Are Urgently Needed: New Priorities for Behavioral Research in the Second Decade of AIDS. *American Psychologist* 1993;48(10):1023-34.
80. McCusker J, Stoddard A, Zapka J, Zorn M, and Mayer K. Predictors of AIDS-preventive behavior among homosexually active men: a longitudinal study. *AIDS* 1989;3(7):443-8.
81. Kelly J, Murphy D. Some lessons learned about risk reduction after ten years of the HIV/AIDS epidemic. *AIDS Care* 1991;3(3):251-7.
82. Kelly JA and Murphy D. Psychological Interventions with AIDS and HIV: Prevention and Treatment. *Journal of Consulting and Clinical Psychology* 1992;60(4):576-85.
83. American Public Health Association. Freudenberg N and Zimmerman M, editors. *AIDS Prevention in the Community: Lessons From the First Decade*. American Public Health Association; 1995.
84. Wiktor S, Biggar R, Melbye M, Ebbesen P, Colclough G, DiGioia R, Sanchez W, Grossman R, and Goedert J. Effect of Knowledge of Human Immunodeficiency Virus Infection Status on Sexual Activity Among Homosexual Men. *Journal of Acquired Immunodeficiency Syndromes* 1990;3(1):62-8.
85. Kelly JA, St.Lawrence J, Betts R, Brasfield T, and Hood H. A Skills-Training Group Intervention Model to Assist Persons In Reducing Risk Behaviors for HIV Infection. *AIDS Education and Prevention* 1990;2(1):24-35.
86. Sikkema KJ, Winett RA, and Lombard DJ. Development and Evaluation of an HIV-Risk Reduction Program for Female College Students. *AIDS Education and Prevention* 1995;7(2):145-59.
87. Kelly JA and Kalichman SC. Increased Attention to Human Sexuality Can Improve HIV-AIDS Prevention Efforts: Key Research Issues and Directions. *Journal of Consulting and Clinical Psychology* 1995;63(6):907-18.
88. Centers for Disease Control and Prevention. *Compendium of HIV Prevention Interventions with Evidence of Effectiveness*. 1999; Atlanta: Centers for Disease Control and Prevention.
89. Higgins D, Galavotti C, O'Reilly K, Schnell D, Moore M, Rugg D, and Johnson R. Evidence for the Effects of HIV Antibody Counseling and Testing on Risk Behaviors. *Journal of the American Medical Association* 1991;266(17):2419-29.
90. Wolitski R, MacGowan R, Higgins D, and Jorgenson C. The Effects of HIV Counseling and Testing on Risk-Related Practices and Help-Seeking Behavior. *AIDS Education and Prevention* 1997;9(Supplement B):52-67.
91. Flaskerud J. Matching client and therapist ethnicity, language, and gender: a review of research. *Issues in Mental Health Nursing* 1990;11(4):321-36.

92. Padian N, O'Brien T, Chang Y, Glass S, and Francis D. Prevention of Heterosexual Transmission of Human Immunodeficiency Virus Through Couple Counseling. *Journal of Acquired Immunodeficiency Syndromes* 1993;6(9):1043-8.
93. Kamenga M, Ryder R, Jingu M, Mbuyi N, Mbu L, Behets F, Brown C, and Heyward W. Evidence of marked sexual behavior change associated with low HIV-1 seroconversion in 149 married couples with discordant HIV-1 serostatus: experience at an HIV counselling center in Zaire. *AIDS* 1991;5(1):61-7.
94. deVincenzi I. A Longitudinal Study of HIV Transmission by Heterosexual Partners. *New England Journal of Medicine* 1994;331:341-6.
95. Levy J, Fox S, Valle M. What you don't know can hurt you: the influence of prior HIV testing on serostatus results at repeat testing. XII International Conference on AIDS; Geneva, Switzerland; 1998; Abstract no. 43113. p. 869.
96. Kilmarx P, Hamers F, Peterman T. Living With HIV : Experiences and Perspectives of HIV-Infected Sexually Transmitted Disease Clinic Patients After Posttest Counseling. *Sexually Transmitted Diseases* 1998;25(1):28-37.
97. Cates W and Handsfield H. HIV Counseling and Testing: Does it Work? *American Journal of Public Health* 1988;78(12):1533-4.
98. Caslyn DA, Saxon AJ, Freeman G, Whittaker S. Ineffectiveness of AIDS education and HIV antibody testing in reducing high risk behaviors among injection drug users. *American Journal of Public Health* 1992;82:573-5.
99. Edlin BR, Irwin KL, Faruque S, Coy C, Word C, Serrano Y, Inciardi JA, Bowser BP, Schilling RF, Holmberg SD. Intersecting epidemics--crack cocaine use and HIV infection among inner-city young adults. *New England Journal of Medicine* 1994;331:1422-7.
100. Cottler LB, Leukefeld DSW, Hoffman J, Desmond D, Wechsberg W, Inciardi JA, Compton WM, Abdallah AB, Cunningham-Williams R, Woodson S. Effectiveness of HIV risk reduction initiatives among out of treatment non-injecting drug users. *Journal of Psychoactive Drugs* 1998;30(3):279-90.
101. Nicolosi A, Molinari S, Musicco M, Saracco A, Ziliani N, and Lazzarin A. Positive modification of injecting behavior among intravenous heroin users from Milan and Northern Italy. *British Journal of Addiction* 1991;86(1):91-102.
102. Neaigus A, Sufian M, Friedman S, Goldsmith D, Stepherson B, Mota P, Pascal J, Des Jarlais D. Effects of Outreach Intervention on Risk Reduction Among Intravenous Drug Users. *AIDS Education and Prevention* 1990;2(4):253-71.
103. Obermayer T and Streeter A. Street Outreach HIV Education to Intravenous Drug Users and Other Substance Abusers. *AIDS Patient Care* 1991;5(1):312-4.
104. Hagan H. Reduced Risk of Hepatitis B and Hepatitis C Among Injection Drug Users in the

- Tacoma Syringe Exchange Program. *American Journal of Public Health* 1995;85:1531-7.
105. Jones T and Vlahov D. Use of sterile syringes and aseptic drug preparation are important components of HIV prevention among injection drug users. *Journal of Acquired Immune Deficiency Syndromes* 1998;18(Supplement 1):1-5.
106. Irwin K, Valdiserri R, and Holmberg S. The acceptability of voluntary HIV antibody testing in the United States: a decade of lessons learned. *AIDS* 1996;10(14):1707-17.
107. Valdiserri RO, Moore M, Gerber RA, Campbell CH, Dillon BA, and West GR. A Study of Clients Returning for Counseling After HIV Testing: Implications for Improving Rates of Return. *Public Health Reports* 1993;108(1):12-8.
108. Otten M, Zaidi A, Wroten J, Witte J, and Peterman T. Changes in Sexually Transmitted Disease Rates after HIV Testing and Posttest Counseling, Miami, 1988 to 1989. *American Journal of Public Health* 1993;83(4):529-33.
109. Catania J, Gibson D, Marin B, Coates T, and Greenblatt RM. Response Bias in Assessing Sexual Behaviors Relevant to HIV Transmission. *Evaluation and Program Planning* 1990;13(1):19-29.
110. Weber T, Frey R, Horsley R, and Gwinn M. Publicly Funded HIV Counseling and Testing in the United States, 1992-1995. *AIDS Education and Prevention* 1997;9(Supplement B):79-91.
111. Branson B, Ballenger A, Olthoff G. HIV Test Results and Post-Test Counseling by Telephone. 1994; Tenth International Conference on AIDS.
112. Schluter W, Judson F, Baron A, McGill W, Marine W, and Douglas J. Usefulness of Human Immunodeficiency Virus Post-Test Counseling by Telephone for Low-Risk Clients of an Urban Sexually Transmitted Diseases Clinic. *Sexually Transmitted Diseases* 1996;23(3):190-7.
113. Samet JH, Freedberg K, Stein M, Lewis R, Savetski J, Sullivan L, Levenson S, and Hingson R. Trillion Virion Delay: Time From Testing Positive for HIV to Prevention for Primary Care. *Archives of Internal Medicine* 1998;158(7):734-40.
114. Varghese B, Maher JE, Peterman TA, et al. Quantifying the reduction in risk for HIV infection by choice of partner, sex act, and condom use. [Abstract] XII International World AIDS Conference, Durban, South Africa, July 9-14, 2000 2000.
115. Centers for Disease Control and Prevention. Update: HIV Counseling and Testing Using Rapid Tests -- United States, 1995. *Morbidity and Mortality Weekly Report* 1998;47(11):211-5.
116. Valdiserri R, Holtgrave DR, and West GR. Promoting early HIV diagnosis and entry into care. *AIDS* 1999;13(17):2317-30.
117. Landesman S, Minkoff H, Holman S, McCalla S, and Sijin O. Serosurvey of Human Immunodeficiency Virus Infection in Parturients: Implications for Human Immunodeficiency Testing Programs of Pregnant Women. *Journal of the American Medical Association* 1987;258(19):2701-3.
118. Barbacci M, Dalabetta G, Repke J, Talbot B, Charache P, Polk F, Chaisson R. Human

Immunodeficiency Virus Infection in Women Attending an Inner-City Prenatal Clinic: Ineffectiveness of Targeted Screening. *Sexually Transmitted Diseases* 1990;17(3):122-6.

119. Barbacci M, Repke J, and Chaisson R. Routine prenatal screening for HIV infection. *The Lancet* 1991;337709-11.
120. Fehrs L, Hill D, Kerndt P, Rose T, Henneman C. Targeted HIV Screening at a Los Angeles Prenatal/Family Planning Health Center. *American Journal of Public Health* 1991;81(5):619-22.
121. Lindsay MK, Peterson H, Willis S, Slade B, Gramling J, Williams H, Klien L. Incidence and prevalence of human immunodeficiency virus infection in a prenatal population undergoing routine voluntary human immunodeficiency virus screening, July 1987 to June 1990. *American Journal of Obstetrics and Gynecology* 1991;165:961-4.
122. Centers for Disease Control and Prevention. HIV Testing Among Populations at Risk for HIV Infection -- Nine States, November 1995-December 1996. *Morbidity and Mortality Weekly Report* 1998;47(50):1086-91.
123. Wykoff R, Jones J, Longshore S, Hollis S, Quiller C, Dowda H, and Gamble W. Notification of the Sex and Needle-Sharing Partners of Individuals With Human Immunodeficiency Virus in Rural South Carolina: 30 Month Experience. *Sexually Transmitted Diseases* 1991;18(4):217-22.
124. Exner T, Ehrhardt A, Loeb I, et al. HIV Counseling and Testing: Women's Experiences and The Role of Testing as a Prevention Strategy. [Abstract] *Int Conf AIDS* 1996;11(2):150 (We.C. 3529).
125. Kassler WJ, Meriwether R, Klimko T, Peterman T, and Zaidi A. Eliminating access to anonymous HIV antibody testing in North Carolina: effects on HIV testing and partner notification. *Journal of Acquired Immune Deficiency Syndromes* 1997;14(3):281-9.
126. Simpson WM, Johnstone FD, Goldberg DJ, Gormley SM, and Hart GJ. Antenatal HIV testing: assessment of a routine voluntary approach. *BMJ* 1999;318:1660-1.
127. Lee J. Targeted opt-in vs. routine opt-out HIV Testing in an STD clinic. 1999 National HIV Prevention Conference, Atlanta, GA, August 29-September 1, Abstract #153.
128. Rahimian A, Driscoll M, Taylor D, et al. Barriers to building a comprehensive system of HIV counseling and testing by consent to women of reproductive age in Chicago, Illinois. [Abstract] *Int Conf AIDS* 1996;11(1):396 (Tu.D. 2772).
129. Federal Trade Commission. Home-Use Tests for HIV Can be Inaccurate, FTC Warns (Consumer Alert). 1999.
130. Centers for Disease Control and Prevention. Identification of HIV-1 Group O Infection - Los Angeles County, California, 1996. *Morbidity and Mortality Weekly Report* 1996;45(26):561-4.
131. Sullivan PS, Do AN, Robbins K, Kalish M, Subbarao S, Pieniazek D, Schable C, Afaq G, Markowitz J, Myers R et al. Surveillance for Variant Strains of HIV: Subtype G and Group O HIV-1 [letter]. *Journal of the American Medical Association* 1997;278(4):292.

132. Centers for Disease Control and Prevention. Human Immunodeficiency Virus Type 2. 1998; Atlanta, (GA): Centers for Disease Control and Prevention.
133. Centers for Disease Control and Prevention. Testing for Antibodies to Human Immunodeficiency Virus Type 2 in the United States. *Morbidity and Mortality Weekly Report: Recommendations and Reports* 1992;41(RR-12):1-9.
134. Centers for Disease Control and Prevention. U.S. Public Health Service Guidelines for Testing and Counseling of Blood and Plasma Donors for Human Immunodeficiency Virus Type 1 Antigen. *Morbidity and Mortality Weekly Report: Recommendations and Reports* 1996;45(RR-2):1-9.
135. Stetler H, Granade T, Nunez C, Meza R, Terrell S, Amador L, and George R. Field evaluation of rapid HIV serologic tests for screening and confirming HIV-1 infection in Honduras. *AIDS* 1997;11(3):369-75.
136. Celum C, Coombs R, Lafferty W, Inui T, Louie P, Gates C, McCreedy B, Egan R, Grove T, Alexander S, et al. Indeterminate Human Immunodeficiency Virus Type 1 Western Blots: Seroconversion Risk, Specificity of Supplemental Tests. *The Journal of Infectious Diseases* 1991;164(4):656-64.
137. Horsburgh R, Ou CH, Jason J, et al. Duration of human immunodeficiency virus infection before detection of antibody. *Lancet* 1989;(2):637-9.
138. Busch MP, Lee LLJ, Satten GA, et al. Time course of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. *Transfusion* 1995;(35):91-7.
139. Jackson JB, MacDonald K, Cadwell J, Sullivan C, Kline W, Hanson M, Sannerud K, Stramer S, Fildes N, Kwok S, et al. Absence of HIV Infection In Blood Donors With Indeterminate Western Blot Tests for Antibody to HIV-1. *The New England Journal of Medicine* 1990;322(1):217-22.
140. Dock NL, Kleinman SH, Rayfield MA, Schable CA, Williams AE, and Dodd RY. Human Immunodeficiency Virus Infection and Indeterminate Western Blot Patterns - Prospective Studies in a Low Prevalence Population. *Archives of Internal Medicine* 1991;151(3):525-30.
141. Ciesielski C and Metler R. Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. *American Journal of Medicine* 1997;(102):115-6.
142. Schochetman G; George JR. *AIDS testing: a comprehensive guide to technical, medical, social, legal, and management issues.* 2 ed. New York: Springer-Verlag; 1994.
143. Nutting P, Main D, Fischer P, Stull T, Pontious M, Seifert M J, Boone D, Holcomb S. Problems in Laboratory Testing in Primary Care [Toward Optimal Laboratory Use]. *Journal of the American Medical Association* 1996;275(8):635-9.
144. Boone D, Steindel S, Herron R, Howanitz P, Bachner P, Meier F, Schiffman R, and Zarbo R.

Transfusion Medicine Monitoring Practices: A study of the College of American Pathologists/Centers for Disease Control and Prevention Outcomes Working Group. *Archives of Pathology and Laboratory Medicine* 1995;119(11):999-1006.

145. Witte D, VanNess S, Angstandt D, and Pennel B. Errors, Mistakes, Blunders, Outliers, or Unacceptable Results: How Many. *Clinical Chemistry* 1997;43(8 Pt. 1):1352-6.
146. Institute of Medicine. Eng TR and Butler WT, editors. *The Hidden Epidemic: Confronting Sexually Transmitted Diseases*. Washington, DC: National Academy Press; 1997.
147. Greenberg JB, MacGowan R, Neumann M, Long A, Cheney R, Fernando D, Sterk C, and Wiebel W. Linking Injection Drug Users to Medical Services: Role of Street Outreach Referrals. *Health and Social Work* 1998;23(4):298-309.
148. Hymel M and Greenberg B. The Walden House Young Adult HIV Project: Meeting the Needs of Multidiagnosed Youth. *Journal of Adolescent Health* 1998;23(2S):122-31.
149. Centers for Disease Control and Prevention. Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. *Morbidity and Mortality Weekly Report: Recommendations and Reports* 1998;47(RR-19):1-39.
150. Centers for Disease Control and Prevention. Framework for Program Evaluation in Public Health. *Morbidity and Mortality Weekly Report* 1999;48(RR-11):1-40.
151. Centers for Disease Control and Prevention. Evaluating CDC-funded health department HIV prevention programs. Volume 1: Guidance. Atlanta, GA: Centers for Disease Control and Prevention; 1999.
152. Centers for Disease Control and Prevention. Adoption of protective behaviors among persons with recent HIV infection and diagnosis—Alabama, New Jersey, and Tennessee, 1997-1998. *Morbidity and Mortality Weekly Report* 2000;49(23):512-5.
153. Kassler WJ, Dillon BA, Haley C, Jones WK, Goldman A. On-site, rapid HIV testing with same-day results and counseling. *AIDS* 1997;11:1045-51.